

Michael Camilleri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/704614/publications.pdf>

Version: 2024-02-01

927
papers

61,985
citations

553

126
h-index

2323

199
g-index

1405
all docs

1405
docs citations

1405
times ranked

25564
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1466-1479.	0.6	1,740
2	AGA technical review on irritable bowel syndrome. <i>Gastroenterology</i> , 2002, 123, 2108-2131.	0.6	1,247
3	Clinical Guideline: Management of Gastroparesis. <i>American Journal of Gastroenterology</i> , 2013, 108, 18-37.	0.2	904
4	Chronic Constipation. <i>New England Journal of Medicine</i> , 2003, 349, 1360-1368.	13.9	692
5	Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2424.	3.8	614
6	Intestinal barrier function in health and gastrointestinal disease. <i>Neurogastroenterology and Motility</i> , 2012, 24, 503-512.	1.6	613
7	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. <i>American Journal of Gastroenterology</i> , 2008, 103, 753-763.	0.2	588
8	Leaky gut: mechanisms, measurement and clinical implications in humans. <i>Gut</i> , 2019, 68, 1516-1526.	6.1	556
9	A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation. <i>New England Journal of Medicine</i> , 2008, 358, 2344-2354.	13.9	527
10	Irritable bowel syndrome: A technical review for practice guideline development. <i>Gastroenterology</i> , 1997, 112, 2120-2137.	0.6	521
11	Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2000, 355, 1035-1040.	6.3	517
12	A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 895-904.	1.9	416
13	Pyloric dysfunction in diabetics with recurrent nausea and vomiting. <i>Gastroenterology</i> , 1986, 90, 1919-1925.	0.6	396
14	Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. <i>Gastroenterology</i> , 2000, 118, 463-468.	0.6	386
15	A Controlled Trial of Gluten-Free Diet in Patients With Irritable Bowel Syndrome-Diarrhea: Effects on Bowel Frequency and Intestinal Function. <i>Gastroenterology</i> , 2013, 144, 903-911.e3.	0.6	386
16	A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. <i>Neurogastroenterology and Motility</i> , 2005, 17, 687-696.	1.6	379
17	Serotonin: A Mediator of The Brain-Gut Connection. <i>American Journal of Gastroenterology</i> , 2000, 95, 2698-2709.	0.2	369
18	Irritable bowel syndrome. <i>Lancet, The</i> , 2020, 396, 1675-1688.	6.3	348

#	ARTICLE	IF	CITATIONS
19	Review article: irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1997, 11, 3-15.	1.9	346
20	Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT ₃ receptor antagonist. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1149-1159.	1.9	342
21	Prevalence and Socioeconomic Impact of Upper Gastrointestinal Disorders in the United States: Results of the US Upper Gastrointestinal Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 543-552.	2.4	339
22	Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. <i>American Journal of Gastroenterology</i> , 2003, 98, 1309-1314.	0.2	322
23	Measurement of gastrointestinal motility in the GI laboratory. <i>Gastroenterology</i> , 1998, 115, 747-762.	0.6	317
24	Mechanisms of hypersensitivity in IBS and functional disorders. <i>Neurogastroenterology and Motility</i> , 2007, 19, 62-88.	1.6	310
25	Abnormal intestinal motility in diabetics with the gastroparesis syndrome. <i>European Journal of Clinical Investigation</i> , 1984, 14, 420-427.	1.7	308
26	Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2017, 152, 1042-1054.e1.	0.6	307
27	Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. <i>Neurogastroenterology and Motility</i> , 2011, 23, 8-23.	1.6	305
28	Diabetic Gastroparesis. <i>New England Journal of Medicine</i> , 2007, 356, 820-829.	13.9	301
29	Management of the irritable bowel syndrome. <i>Gastroenterology</i> , 2001, 120, 652-668.	0.6	299
30	Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G775-G785.	1.6	299
31	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. <i>Journal of Nuclear Medicine Technology</i> , 2008, 36, 44-54.	0.4	295
32	Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings.. <i>Gut</i> , 1987, 28, 5-12.	6.1	288
33	The stomach in health and disease. <i>Gut</i> , 2015, 64, 1650-1668.	6.1	283
34	Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. <i>Gastroenterology</i> , 2001, 120, 354-360.	0.6	278
35	A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome. <i>Archives of Internal Medicine</i> , 2001, 161, 1733.	4.3	275
36	Review article: metoclopramide and tardive dyskinesia. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 11-19.	1.9	270

#	ARTICLE	IF	CITATIONS
37	Dietary Fiber Supplements: Effects in Obesity and Metabolic Syndrome and Relationship to Gastrointestinal Functions. <i>Gastroenterology</i> , 2010, 138, 65-72.e2.	0.6	269
38	Relationship between impaired gastric emptying and abnormal gastrointestinal motility. <i>Gastroenterology</i> , 1986, 91, 94-99.	0.6	266
39	Peripheral Mechanisms in Irritable Bowel Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 1626-1635.	13.9	266
40	Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. <i>Gastroenterology</i> , 2015, 149, 340-349.e2.	0.6	262
41	Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. <i>Gastroenterology</i> , 2002, 123, 425-432.	0.6	261
42	Obesity is Associated with Increased Risk of Gastrointestinal Symptoms: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2004, 99, 1801-1806.	0.2	258
43	Scintigraphic measurement of regional gut transit in idiopathic constipation. <i>Gastroenterology</i> , 1991, 101, 107-115.	0.6	251
44	Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. <i>Gastroenterology</i> , 1991, 100, 137-142.	0.6	241
45	Epidemiology, Mechanisms, and Management of Diabetic Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 5-12.	2.4	238
46	Systematic review: cardiovascular safety profile of 5-HT ₄ agonists developed for gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 745-767.	1.9	236
47	Gastroparesis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 41.	18.1	235
48	Effect of 5 Days Linaclotide on Transit and Bowel Function in Females With Constipation-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2007, 133, 761-768.	0.6	234
49	Gastrointestinal Tract Symptoms Among Persons With Diabetes Mellitus in the Community. <i>Archives of Internal Medicine</i> , 2000, 160, 2808.	4.3	228
50	Endoscopic Sleeve Gastroplasty Alters Gastric Physiology and Induces Loss of Body Weight in Obese Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 37-43.e1.	2.4	222
51	American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. <i>Neurogastroenterology and Motility</i> , 2008, 20, 1269-1282.	1.6	217
52	Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome. <i>Cell</i> , 2020, 182, 1460-1473.e17.	13.5	217
53	Opioid-Induced Constipation: Challenges and Therapeutic Opportunities. <i>American Journal of Gastroenterology</i> , 2011, 106, 835-842.	0.2	216
54	Management of functional constipation in children and adults. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 21-39.	8.2	216

#	ARTICLE	IF	CITATIONS
55	Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. <i>Gastroenterology</i> , 2004, 127, 1685-1694.	0.6	214
56	Serotonin: a mediator of the brain-gut connection. <i>American Journal of Gastroenterology</i> , 2000, 95, 2698-2709.	0.2	213
57	Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G942-G947.	1.6	213
58	Prospective Study of Motor, Sensory, Psychologic, and Autonomic Functions in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 772-781.e5.	2.4	212
59	Gastric electromechanical and neurohormonal function in anorexia nervosa. <i>Gastroenterology</i> , 1987, 93, 958-965.	0.6	210
60	Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. <i>Neurogastroenterology and Motility</i> , 2003, 15, 79-86.	1.6	209
61	Integrated Upper Gastrointestinal Response to Food Intake. <i>Gastroenterology</i> , 2006, 131, 640-658.	0.6	209
62	Selective stimulation of colonic transit by the benzofuran 5HT ₄ agonist, prucalopride, in healthy humans. <i>Gut</i> , 1999, 44, 682-686.	6.1	203
63	Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17095.	18.1	203
64	Human enteric neuropathies: morphology and molecular pathology. <i>Neurogastroenterology and Motility</i> , 2004, 16, 515-531.	1.6	200
65	SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. <i>Gut</i> , 2002, 51, 781-786.	6.1	195
66	Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 545-555.	2.4	194
67	Opioids and the gut: pharmacology and current clinical experience. <i>Neurogastroenterology and Motility</i> , 2004, 16, 383-394.	1.6	193
68	Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 264-272.	2.4	191
69	Towards a less costly but accurate test of gastric emptying and small bowel transit. <i>Digestive Diseases and Sciences</i> , 1991, 36, 609-615.	1.1	188
70	[¹³ C]octanoic acid breath test for gastric emptying of solids: Accuracy, reproducibility, and comparison with scintigraphy. <i>Gastroenterology</i> , 1997, 112, 1155-1162.	0.6	187
71	Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes. <i>Diabetes</i> , 2007, 56, 1475-1480.	0.3	187
72	Transit through the proximal colon influences stool weight in the irritable bowel syndrome. <i>Gastroenterology</i> , 1992, 102, 102-108.	0.6	186

#	ARTICLE	IF	CITATIONS
73	Rumination Syndrome in Children and Adolescents: Diagnosis, Treatment, and Prognosis. <i>Pediatrics</i> , 2003, 111, 158-162.	1.0	185
74	Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. <i>Neurogastroenterology and Motility</i> , 2010, 22, 874.	1.6	185
75	Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. <i>Gut</i> , 2008, 57, 1140-1155.	6.1	178
76	Increased Bile Acid Biosynthesis Is Associated With Irritable Bowel Syndrome With Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1009-1015.e3.	2.4	178
77	Visceral hypersensitivity: facts, speculations, and challenges. <i>Gut</i> , 2001, 48, 125-131.	6.1	176
78	Tegaserod. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 277-289.	1.9	172
79	A Stable Isotope Breath Test With a Standard Meal for Abnormal Gastric Emptying of Solids in the Clinic and in Research. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 635-643.e1.	2.4	172
80	Modulation of gastric sensory and motor functions by nitrenergic and β -adrenergic agents in humans. <i>Gastroenterology</i> , 1999, 116, 573-585.	0.6	171
81	Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. <i>Neurogastroenterology and Motility</i> , 2010, 22, 113-133.	1.6	171
82	Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1386-1395.	1.6	171
83	Bile Acid Diarrhea: Prevalence, Pathogenesis, and Therapy. <i>Gut and Liver</i> , 2015, 9, 332-9.	1.4	171
84	Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1781-1790.	1.9	170
85	Advances in the diagnosis and classification of gastric and intestinal motility disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 291-308.	8.2	168
86	Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. <i>Nature Communications</i> , 2019, 10, 2012.	5.8	168
87	Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel Function. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 159-165.e5.	2.4	166
88	Motor Dysfunction of the Small Bowel and Colon in Patients with the Carcinoid Syndrome and Diarrhea. <i>New England Journal of Medicine</i> , 1993, 329, 1073-1078.	13.9	165
89	Association of distinct β 2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. <i>Gut</i> , 2004, 53, 829-837.	6.1	165
90	Gastrointestinal Complications of Obesity. <i>Gastroenterology</i> , 2017, 152, 1656-1670.	0.6	164

#	ARTICLE	IF	CITATIONS
91	Peripheral Mechanisms in Appetite Regulation. <i>Gastroenterology</i> , 2015, 148, 1219-1233.	0.6	163
92	Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, G424-G431.	1.6	162
93	Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. <i>Gastroenterology</i> , 1995, 109, 755-765.	0.6	160
94	Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon. <i>Gastroenterology</i> , 1995, 109, 1772-1780.	0.6	159
95	Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. <i>Gastroenterology</i> , 2000, 119, 41-50.	0.6	158
96	Idiopathic autonomic neuropathy. <i>Neurology</i> , 1994, 44, 1675-1675.	1.5	158
97	A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 1803-1812.	0.2	156
98	Current management strategies and emerging treatments for functional dyspepsia. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 187-194.	8.2	155
99	Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis. <i>Gastroenterology</i> , 2010, 139, 1549-1558.e1.	0.6	154
100	Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. <i>Gastroenterology</i> , 1989, 96, 704-712.	0.6	153
101	Clinical and Upper Gastrointestinal Motility Features in Systemic Sclerosis and Related Disorders. <i>American Journal of Gastroenterology</i> , 1998, 93, 1085-1089.	0.2	151
102	Relation between antral motility and gastric emptying of solids and liquids in humans. <i>American Journal of Physiology - Renal Physiology</i> , 1985, 249, G580-G585.	1.6	150
103	Gastric accommodation in non-ulcer dyspepsia and the roles of <i>Helicobacter pylori</i> infection and vagal function. <i>Gut</i> , 1999, 44, 55-64.	6.1	150
104	Paraneoplastic Gastrointestinal Motor Dysfunction: Clinical and Laboratory Characteristics. <i>American Journal of Gastroenterology</i> , 2001, 96, 373-379.	0.2	150
105	Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. <i>Gut</i> , 2019, 68, 804-813.	6.1	147
106	Symptomatic overlap between irritable bowel syndrome and microscopic colitis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 175-181.	0.9	146
107	Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 264-272.	2.4	145
108	Peripheral Mechanisms in Irritable Bowel Syndrome. <i>New England Journal of Medicine</i> , 2013, 368, 577-579.	13.9	144

#	ARTICLE	IF	CITATIONS
109	Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1657-1666.	1.6	144
110	Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. <i>American Journal of Gastroenterology</i> , 2001, 96, 3099-3105.	0.2	143
111	Independent influences of body mass and gastric volumes on satiation in humans. <i>Gastroenterology</i> , 2004, 126, 432-440.	0.6	143
112	Quantitative Gastrointestinal and Psychological Traits Associated With Obesity and Response to Weight-Loss Therapy. <i>Gastroenterology</i> , 2015, 148, 537-546.e4.	0.6	143
113	The rumination syndrome: Clinical features rather than manometric diagnosis. <i>Gastroenterology</i> , 1995, 108, 1024-1029.	0.6	142
114	Serotonin in the gastrointestinal tract. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 53-59.	1.2	142
115	Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. <i>Gastroenterology</i> , 1989, 96, 110-115.	0.6	140
116	Neurohormonal Factors in Functional Dyspepsia: Insights on Pathophysiological Mechanisms. <i>Gastroenterology</i> , 1991, 100, 1311-1318.	0.6	140
117	A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 985-996.	2.4	140
118	Intra-abdominal vagal blocking (VBLOC therapy): Clinical results with a new implantable medical device. <i>Surgery</i> , 2008, 143, 723-731.	1.0	140
119	Impaired transit of chyme in chronic intestinal pseudoobstruction. <i>Gastroenterology</i> , 1986, 91, 619-626.	0.6	137
120	Measurement of serum 7α -hydroxy $^4\beta$ -cholesten $^3\alpha$ -one (or 7α -C4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. <i>Neurogastroenterology and Motility</i> , 2009, 21, 734.	1.6	135
121	Effect of age on the enteric nervous system of the human colon. <i>Neurogastroenterology and Motility</i> , 2009, 21, 746.	1.6	134
122	Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. <i>Neurogastroenterology and Motility</i> , 2012, 24, 1076.	1.6	133
123	Bowel Functions, Fecal Unconjugated Primary and Secondary Bile Acids, and Colonic Transit in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1270-1275.e1.	2.4	132
124	Accuracy, Safety, and Tolerability of Tissue Collection by Cytosponge vs Endoscopy for Evaluation of Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 77-83.e2.	2.4	132
125	Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. <i>Gut</i> , 2017, 66, 1611-1622.	6.1	132
126	Variation of muscle tone in the human colon. <i>Gastroenterology</i> , 1991, 101, 373-381.	0.6	131

#	ARTICLE	IF	CITATIONS
127	Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. <i>Clinical Endocrinology</i> , 2009, 70, 415-420.	1.2	131
128	Human gastric emptying and colonic filling of solids characterized by a new method. <i>American Journal of Physiology - Renal Physiology</i> , 1989, 257, G284-G290.	1.6	128
129	Intestinal permeability and irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2007, 19, 545-552.	1.6	128
130	Diagnosis and Treatment of Irritable Bowel Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 865.	3.8	128
131	Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. <i>Digestive Diseases and Sciences</i> , 1991, 36, 616-620.	1.1	127
132	Autonomic dysfunction in gastrointestinal motility disorders.. <i>Gut</i> , 1993, 34, 397-401.	6.1	127
133	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. <i>Pharmacological Reviews</i> , 2021, 73, 310-520.	7.1	127
134	Systematic review with meta-analysis: highly selective 5-HT ₄ agonists (prucalopride, velusetrag or Tj ETQq0 0 Q rgBT /Overlock 10 T	1.9	126
135	Endoscopic Mucosal Impedance Measurements Correlate With Eosinophilia and Dilatation of Intercellular Spaces in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1242-1248.e1.	2.4	126
136	Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. <i>Gastroenterology</i> , 2017, 153, 1240-1250.e2.	0.6	125
137	Effect of Alvimopan and Codeine on Gastrointestinal Transit: A Randomized Controlled Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 784-791.	2.4	124
138	Contribution of Endogenous Glucagon-Like Peptide 1 to Glucose Metabolism After Roux-en-Y Gastric Bypass. <i>Diabetes</i> , 2014, 63, 483-493.	0.3	123
139	Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 890-899.	3.7	123
140	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 74-82.	6.1	122
141	Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. <i>Gastroenterology</i> , 1989, 96, 704-12.	0.6	122
142	Serotonergic mediation of postprandial colonic tonic and phasic responses in humans.. <i>Gut</i> , 1994, 35, 536-541.	6.1	121
143	Gastroparesis: Clinical Update. CME. <i>American Journal of Gastroenterology</i> , 2006, 101, 1129-1139.	0.2	120
144	Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. <i>Neurogastroenterology and Motility</i> , 2009, 21, 1256.	1.6	120

#	ARTICLE	IF	CITATIONS
145	Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. <i>Neurogastroenterology and Motility</i> , 2010, 22, 293-e82.	1.6	120
146	Loss-of-Function of the Voltage-Gated Sodium Channel NaV1.5 (Channelopathies) in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2014, 146, 1659-1668.	0.6	120
147	Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. <i>Gut</i> , 2018, 67, 263-270.	6.1	120
148	Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. <i>Gastroenterology</i> , 1992, 103, 36-42.	0.6	119
149	Differences in colonic tone and phasic response to a meal in the transverse and sigmoid human colon. <i>Gut</i> , 1995, 37, 264-269.	6.1	117
150	Alterations in Mucosal Immunity Identified in the Colon of Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 194-205.	2.4	117
151	Regional gastrointestinal transit and pH studied in 215 healthy volunteers using the wireless motility capsule: influence of age, gender, study country and testing protocol. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 761-772.	1.9	117
152	Audit of constipation in a tertiary referral gastroenterology practice. <i>American Journal of Gastroenterology</i> , 1995, 90, 1471-5.	0.2	117
153	Alterations in Expression of p11 and SERT in Mucosal Biopsy Specimens of Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2007, 132, 17-25.	0.6	116
154	Effects of A3309, an Ileal Bile Acid Transporter Inhibitor, on Colonic Transit and Symptoms in Females With Functional Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 2154-2164.	0.2	116
155	Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 537-547.	3.7	116
156	Parkinson disease and the gut: new insights into pathogenesis and clinical relevance. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 673-685.	8.2	116
157	The Irritable Bowel Syndrome: Mechanisms and a Practical Approach to Management. <i>Annals of Internal Medicine</i> , 1992, 116, 1001-1008.	2.0	115
158	Clinical Management of Intractable Constipation. <i>Annals of Internal Medicine</i> , 1994, 121, 520.	2.0	115
159	Dietary and pharmacological treatment of abdominal pain in IBS. <i>Gut</i> , 2017, 66, 966-974.	6.1	115
160	Reproducibility and Simplification of ¹³ C-Octanoic Acid Breath Test for Gastric Emptying of Solids. <i>American Journal of Gastroenterology</i> , 1998, 93, 92-98.	0.2	114
161	A Study of Candidate Genotypes Associated with Dyspepsia in a U.S. Community. <i>American Journal of Gastroenterology</i> , 2006, 101, 581-592.	0.2	114
162	Effects of Pro-motility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2019, 156, 1650-1660.	0.6	114

#	ARTICLE	IF	CITATIONS
163	A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. <i>Neurogastroenterology and Motility</i> , 2002, 14, 249-253.	1.6	113
164	Assessment of gastric accommodation: overview and evaluation of current methods. <i>Neurogastroenterology and Motility</i> , 2004, 16, 275-285.	1.6	112
165	Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis. <i>Gastroenterology</i> , 2016, 151, 87-96.e6.	0.6	112
166	Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 895-904.	2.4	111
167	Effect of daikenchuto (TU-100) on gastrointestinal and colonic transit in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, G970-G975.	1.6	111
168	Development and content validity of a gastroparesis cardinal symptom index daily diary. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 670-680.	1.9	110
169	Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1338-1349.	2.4	110
170	Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G130-G137.	1.6	109
171	Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. <i>Neurogastroenterology and Motility</i> , 2006, 18, 831-838.	1.6	109
172	Association of TNFSF15 polymorphism with irritable bowel syndrome. <i>Gut</i> , 2011, 60, 1671-1677.	6.1	109
173	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 117-131.	3.7	108
174	Adrenergic modulation of human colonic motor and sensory function. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 273, G997-G1006.	1.6	106
175	Consensus report: clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1407-1430.	1.9	106
176	Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. <i>Neurogastroenterology and Motility</i> , 2002, 14, 123-131.	1.6	106
177	Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G1299-G1306.	1.6	106
178	Common Genetic Variation in <i>GLP1R</i> and Insulin Secretion in Response to Exogenous GLP-1 in Nondiabetic Subjects. <i>Diabetes Care</i> , 2010, 33, 2074-2076.	4.3	106
179	Methods for Diagnosis of Bile Acid Malabsorption in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1232-1239.	2.4	106
180	Gender-related differences in slowing colonic transit by a 5-HT ₃ antagonist in subjects with diarrhea-predominant irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2001, 96, 2671-2676.	0.2	105

#	ARTICLE	IF	CITATIONS
181	Descending Perineum Syndrome: Audit of Clinical and Laboratory Features and Outcome of Pelvic Floor Retraining. <i>American Journal of Gastroenterology</i> , 1999, 94, 126-130.	0.2	104
182	Fundamentals of Neurogastroenterology: Physiology/Motility â€“ Sensation. <i>Gastroenterology</i> , 2016, 150, 1292-1304.e2.	0.6	103
183	Effect of CCK-1 Antagonist, Dexloxiglumide, in Female Patients with Irritable Bowel Syndrome: A Pharmacodynamic and Pharmacogenomic Study. <i>American Journal of Gastroenterology</i> , 2005, 100, 652-663.	0.2	102
184	Probiotics and Irritable Bowel Syndrome: Rationale, Putative Mechanisms, and Evidence of Clinical Efficacy. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 264-269.	1.1	102
185	Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. <i>Gastroenterology</i> , 2017, 152, 515-532.e2.	0.6	102
186	Pharmacodynamic effects of a novel prokinetic 5-HT ₄ receptor agonist, ATI-7505, in humans. <i>Neurogastroenterology and Motility</i> , 2007, 19, 30-38.	1.6	101
187	Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 343-352.	8.2	101
188	Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G919-G928.	1.6	101
189	Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Indexâ€“Daily Diary (GCSIâ€“DD). <i>Neurogastroenterology and Motility</i> , 2012, 24, 456-463.	1.6	101
190	Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis. <i>Gut</i> , 2016, 65, 1951-1959.	6.1	101
191	Chronic Diarrhea in Diabetes Mellitus: Mechanisms and an Approach to Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 1993, 68, 691-702.	1.4	99
192	Methods for measurement of gastric motility. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G461-G475.	1.6	98
193	Gastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People. <i>Gastroenterology</i> , 2006, 131, 1717-1724.	0.6	97
194	Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G1075-G1084.	1.6	97
195	The Ghrelin Agonist RM-131 Accelerates Gastric Emptying of Solids and Reduces Symptoms in Patients With Type 1 Diabetes Mellitus. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1453-1459.e4.	2.4	97
196	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015, 64, 1774-1782.	6.1	97
197	Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion. <i>Neurogastroenterology and Motility</i> , 2010, 22, e15-26.	1.6	96
198	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021, 53, 1543-1552.	9.4	96

#	ARTICLE	IF	CITATIONS
199	Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G137-G145.	1.6	95
200	Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. <i>Pain Medicine</i> , 2015, 16, 2324-2337.	0.9	95
201	Differential regional effects of octreotide on human gastrointestinal motor function.. <i>Gut</i> , 1995, 36, 743-748.	6.1	94
202	Effects of Velusetrag (TDâ€5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. <i>Neurogastroenterology and Motility</i> , 2010, 22, 42.	1.6	93
203	Cannabinoids in intestinal inflammation and cancer. <i>Pharmacological Research</i> , 2009, 60, 117-125.	3.1	93
204	Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. <i>Neurogastroenterology and Motility</i> , 2010, 22, 415-e95.	1.6	93
205	Randomized Controlled Phase Ib Study of Ghrelin Agonist, RM-131, in Type 2 Diabetic Women With Delayed Gastric Emptying. <i>Diabetes Care</i> , 2013, 36, 41-48.	4.3	93
206	Scintigraphy of the Whole Gut: Clinical Evaluation of Transit Disorders. <i>Mayo Clinic Proceedings</i> , 1995, 70, 113-118.	1.4	92
207	Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women. <i>Neurogastroenterology and Motility</i> , 2006, 18, 911-918.	1.6	92
208	Transit of solids through the human colon: regional quantification in the unprepared bowel. <i>American Journal of Physiology - Renal Physiology</i> , 1990, 258, G856-G862.	1.6	91
209	Comparison of the postural tachycardia syndrome (POTS) with orthostatic hypotension due to autonomic failure. <i>Journal of the Autonomic Nervous System</i> , 1994, 50, 181-188.	1.9	91
210	Validation of a stable isotope gastric emptying test for normal, accelerated or delayed gastric emptying. <i>Neurogastroenterology and Motility</i> , 2001, 13, 567-574.	1.6	91
211	Effect of colesevelam on faecal bile acids and bowel functions in diarrhoeaâ€predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 438-448.	1.9	91
212	Stasis Syndromes Following Gastric Surgery. <i>Journal of Clinical Gastroenterology</i> , 1990, 12, 505-512.	1.1	90
213	Rectal tone, distensibility, and perception: reproducibility and response to different distensions. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 274, G584-G590.	1.6	90
214	Effects of a μ -opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G558-G566.	1.6	89
215	Prokinetics in Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 97-111.	1.0	89
216	Economic Burden of Irritable Bowel Syndrome. <i>Pharmacoeconomics</i> , 2000, 17, 331-338.	1.7	88

#	ARTICLE	IF	CITATIONS
217	Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation. <i>Gut</i> , 2012, 61, 1132-1139.	6.1	88
218	Development of a test to measure gastric accommodation in humans. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 277, G1217-G1221.	1.6	87
219	INTESTINAL PSEUDO-OBSTRUCTION. <i>Annual Review of Medicine</i> , 1999, 50, 37-55.	5.0	87
220	Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 831-844.	3.7	87
221	Gastrointestinal motility disturbances in patients with orthostatic hypotension. <i>Gastroenterology</i> , 1985, 88, 1852-1859.	0.6	86
222	Near-total completion gastrectomy for severe postvagotomy gastric stasis: analysis of early and long-term results in 62 patients. <i>Journal of Gastrointestinal Surgery</i> , 1999, 3, 15-23.	0.9	86
223	Gastric Motor and Sensory Functions in Obesity. <i>Obesity</i> , 2005, 13, 491-500.	4.0	85
224	New developments in the treatment of gastroparesis and functional dyspepsia. <i>Current Opinion in Pharmacology</i> , 2018, 43, 111-117.	1.7	85
225	Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 211-218.	2.4	85
226	Disorders of Gastrointestinal Motility in Neurologic Diseases. <i>Mayo Clinic Proceedings</i> , 1990, 65, 825-846.	1.4	84
227	Control of muscle tone in the human colon.. <i>Gut</i> , 1992, 33, 541-546.	6.1	84
228	Psychological Disorders in Patients With Evacuation Disorders and Constipation in A Tertiary Practice. <i>American Journal of Gastroenterology</i> , 2000, 95, 1755-1758.	0.2	84
229	Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients With Nonconstipated Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2011, 141, 1638-1647.e7.	0.6	84
230	Methods for the Assessment of Small-Bowel and Colonic Transit. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 113-123.	2.5	84
231	Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. <i>Gastroenterology</i> , 1991, 100, 252-258.	0.6	83
232	Novel Testing of Human Gastric Motor and Sensory Functions: Rationale, Methods, and Potential Applications in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2000, 95, 3365-3373.	0.2	83
233	Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of Endpoints. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 534-540.	2.4	83
234	Effect of a 5HT ₃ antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1993, 7, 543-551.	1.9	83

#	ARTICLE	IF	CITATIONS
235	Effects of Topical Steroids on Tight Junction Proteins and Spongiosis in Esophageal Epithelia of Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1824-1829.e1.	2.4	83
236	Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. <i>Journal of Nuclear Medicine</i> , 1997, 38, 1807-10.	2.8	83
237	Phenotypic Variation of Colonic Motor Functions in Chronic Constipation. <i>Gastroenterology</i> , 2010, 138, 89-97.	0.6	82
238	Recent advances in clinical practice challenges and opportunities in the management of obesity. <i>Gut</i> , 2014, 63, 687-695.	6.1	82
239	Effect of Increased Bile Acid Synthesis or Fecal Excretion in Irritable Bowel Syndrome-Diarrhea. <i>American Journal of Gastroenterology</i> , 2014, 109, 1621-1630.	0.2	82
240	Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 264-72.	2.4	82
241	Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. <i>Journal of Pediatrics</i> , 2005, 146, 500-505.	0.9	81
242	Effects of glucagon-like peptide-1, yohimbine, and nitroergic modulation on sympathetic and parasympathetic activity in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008, 295, R874-R880.	0.9	81
243	A Klotho ² Variant Mediates Protein Stability and Associates With Colon Transit in Irritable Bowel Syndrome With Diarrhea. <i>Gastroenterology</i> , 2011, 140, 1934-1942.	0.6	81
244	Effects of a serotonin 5-HT ₄ receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. <i>Gut</i> , 2000, 47, 667-674.	6.1	80
245	Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation – follow-up of patients from the pivotal studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1113-1123.	1.9	80
246	Review article: colonic sensorimotor physiology in health, and its alteration in constipation and diarrhoeal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 287-302.	1.9	79
247	A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 111-121.	2.4	79
248	Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 930-936.	1.9	79
249	Advances in understanding of bile acid diarrhea. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 49-61.	1.4	79
250	Opioid-induced constipation: advances and clinical guidance. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 121-134.	1.1	79
251	A valid, accurate, office based non-radioactive test for gastric emptying of solids. <i>Gut</i> , 2000, 46, 768-773.	6.1	78
252	Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. <i>Gut</i> , 2003, 52, 1555-1561.	6.1	78

#	ARTICLE	IF	CITATIONS
253	Alvimopan, a selective peripherally acting mu-opioid antagonist*. Neurogastroenterology and Motility, 2005, 17, 157-165.	1.6	78
254	Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. American Journal of Physiology - Renal Physiology, 2008, 294, G13-G19.	1.6	78
255	Jejunal manometry in distal subacute mechanical obstruction: significance of prolonged simultaneous contractions.. Gut, 1989, 30, 468-475.	6.1	77
256	New-generation 5-HT ₄ receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opinion on Investigational Drugs, 2010, 19, 765-775.	1.9	77
257	Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms. Journal of Physiology, 2014, 592, 2967-2980.	1.3	77
258	Effects of dietary components on intestinal permeability in health and disease. American Journal of Physiology - Renal Physiology, 2020, 319, G589-G608.	1.6	77
259	A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut, 2013, 62, 708-715.	6.1	76
260	Management Options for Irritable Bowel Syndrome. Mayo Clinic Proceedings, 2018, 93, 1858-1872.	1.4	76
261	Autonomic function and motility in intestinal pseudoobstruction caused by paraneoplastic syndrome. Digestive Diseases and Sciences, 1989, 34, 1937-1942.	1.1	75
262	Relationship Between Glycemic Control and Gastric Emptying in Poorly Controlled Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 2015, 13, 466-476.e1.	2.4	75
263	Ileocolonic transfer of solid chyme in small intestinal neuropathies and myopathies. Gastroenterology, 1990, 99, 158-164.	0.6	74
264	Study of human gastroduodenojejunal motility. Digestive Diseases and Sciences, 1993, 38, 785-794.	1.1	74
265	Human gastric and jejunal transit and motility after Roux gastrojejunostomy. Gastroenterology, 1992, 103, 1133-1143.	0.6	73
266	Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clinical Gastroenterology and Hepatology, 2003, 1, 211-218.	2.4	73
267	Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterology and Motility, 2004, 16, 135-142.	1.6	73
268	Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therapeutic Advances in Gastroenterology, 2015, 8, 206-220.	1.4	73
269	Idiopathic autonomic denervation in eight patients presenting with functional gastrointestinal disease. Digestive Diseases and Sciences, 1990, 35, 609-616.	1.1	72
270	Serotonergic modulation of visceral sensation: lower gut. Gut, 2002, 51, i81-i86.	6.1	72

#	ARTICLE	IF	CITATIONS
271	Barostat testing of rectal sensation and compliance in humans: comparison of results across two centres and overall reproducibility. <i>Neurogastroenterology and Motility</i> , 2005, 17, 810-820.	1.6	72
272	Elobixibat and its potential role in chronic idiopathic constipation. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 167-175.	1.4	72
273	Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. <i>Gut</i> , 2018, 67, 1543-1552.	6.1	72
274	Motility disorders and stress. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1777-1786.	1.1	71
275	An Open Trial of Octreotide Long-Acting Release in the Management of Short Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2001, 96, 1494-1498.	0.2	71
276	Does gall-bladder ejection fraction on cholecystokinin cholescintigraphy predict outcome after cholecystectomy in suspected functional biliary pain?. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 167-174.	1.9	71
277	Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome—diarrhea. <i>Neurogastroenterology and Motility</i> , 2012, 24, 358.	1.6	71
278	Definitions and Outcome Measures of Clinical Trials Regarding Opioid-induced Constipation. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 9-16.	1.1	71
279	Effects of an α_2 -adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 281, G1468-G1476.	1.6	70
280	Efficacy of On-Demand Asimadoline, a Peripheral μ -Opioid Agonist, in Females With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1268-1275.	2.4	70
281	Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e173.	1.3	70
282	Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic. <i>Obesity</i> , 2021, 29, 662-671.	1.5	70
283	SDZ HTF 919 stimulates canine colonic motility and transit in vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1997, 280, 1270-6.	1.3	69
284	Measurement of Small Bowel and Colonic Transit: Indications and Methods. <i>Mayo Clinic Proceedings</i> , 1992, 67, 1169-1179.	1.4	68
285	Functional dyspepsia, upper gastrointestinal symptoms, and transit in children. <i>Journal of Pediatrics</i> , 2003, 143, 609-613.	0.9	68
286	Apoptotic cell death of human interstitial cells of Cajal. <i>Neurogastroenterology and Motility</i> , 2009, 21, 85-93.	1.6	68
287	Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2357-2372.	1.1	68
288	Gastrointestinal motility disorders in neurologic disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	68

#	ARTICLE	IF	CITATIONS
289	Motility and tone of the left colon in constipation: a role in clinical practice?. American Journal of Gastroenterology, 1996, 91, 2532-8.	0.2	68
290	A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology, 1994, 106, 1184-1189.	0.6	67
291	Effect of Alginate on Satiety, Appetite, Gastric Function, and Selected Gut Satiety Hormones in Overweight and Obesity. Obesity, 2010, 18, 1579-1584.	1.5	67
292	Functional Dyspepsia and Gastroparesis. Digestive Diseases, 2016, 34, 491-499.	0.8	67
293	Gastric Motor Dysfunction in Patients With Functional Gastrointestinal Symptoms. American Journal of Gastroenterology, 2017, 112, 1689-1699.	0.2	67
294	Toward Office-Based Measurement of Gastric Emptying in Symptomatic Diabetics Using [13C]Octanoic Acid Breath Test. American Journal of Gastroenterology, 2000, 95, 2751-2761.	0.2	66
295	Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterology and Motility, 2003, 15, 435-443.	1.6	66
296	Application of magnetic resonance imaging to measure fasting and postprandial volumes in humans. Neurogastroenterology and Motility, 2009, 21, 42-51.	1.6	66
297	Associations among binge eating behavior patterns and gastrointestinal symptoms: a population-based study. International Journal of Obesity, 2009, 33, 342-353.	1.6	66
298	Psychometric Evaluation of Patient-Reported Outcomes in Irritable Bowel Syndrome Randomized Controlled Trials: A Rome Foundation Report. Gastroenterology, 2009, 137, 1944-1953.e3.	0.6	66
299	Novel Diet, Drugs, and Gastric Interventions for Gastroparesis. Clinical Gastroenterology and Hepatology, 2016, 14, 1072-1080.	2.4	66
300	Gastrointestinal hormones and regulation of gastric emptying. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 3-10.	1.2	66
301	Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Alimentary Pharmacology and Therapeutics, 2000, 14, 783-793.	1.9	65
302	Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles. Gastroenterology, 2008, 135, 1877-1891.	0.6	65
303	Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. Clinical Gastroenterology and Hepatology, 2019, 17, 2471-2478.e3.	2.4	65
304	Evaluation of an inexpensive screening scintigraphic test of gastric emptying. Journal of Nuclear Medicine, 1995, 36, 93-6.	2.8	65
305	Is There a Role for Gastric Accommodation and Satiety in Asymptomatic Obese People?. Obesity, 2001, 9, 655-661.	4.0	64
306	Irritable Bowel Syndrome. Drugs, 2006, 66, 1073-1088.	4.9	64

#	ARTICLE	IF	CITATIONS
307	Brain-Gut Axis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 54, 446-453.	0.9	64
308	Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1673-1676.	2.4	64
309	Chronic nausea and vomiting: evaluation and treatment. <i>American Journal of Gastroenterology</i> , 2018, 113, 647-659.	0.2	64
310	Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 171-192.	0.8	64
311	Novel pharmacology: asimadoline, a μ -opioid agonist, and visceral sensation. <i>Neurogastroenterology and Motility</i> , 2008, 20, 971-979.	1.6	63
312	Therapeutic targeting of bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G209-G215.	1.6	63
313	The surgeon's role in the treatment of chronic intestinal pseudoobstruction. <i>American Journal of Gastroenterology</i> , 1995, 90, 2147-51.	0.2	63
314	Enteric neurodegeneration in ageing. <i>Neurogastroenterology and Motility</i> , 2008, 20, 418-429.	1.6	62
315	Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13370.	1.6	62
316	Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G295-G301.	1.6	61
317	Changes in Time of Gastric Emptying After Surgical and Endoscopic Bariatrics and Weight Loss: A Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 57-68.e5.	2.4	61
318	Dose-related effects of chenodeoxycholic acid in the rabbit colon. <i>Digestive Diseases and Sciences</i> , 1980, 25, 433-438.	1.1	60
319	Chronic Intestinal Pseudo-Obstruction: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 1989, 64, 60-70.	1.4	60
320	Effect of Gastric Volume or Emptying on Meal-Related Symptoms After Liquid Nutrients in Obesity: A Pharmacologic Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 997-1006.	2.4	60
321	Enteric neurodegeneration in ageing. <i>Neurogastroenterology and Motility</i> , 2008, 20, 185-196.	1.6	60
322	Diagnostic Assessment of Diabetic Gastroparesis. <i>Diabetes</i> , 2013, 62, 2667-2673.	0.3	60
323	Role for diet in normal gut barrier function: developing guidance within the framework of food-labeling regulations. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G17-G39.	1.6	60
324	GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1552-1563.	1.8	60

#	ARTICLE	IF	CITATIONS
325	Adynamic ileus in severe Guillain-Barré syndrome. <i>Muscle and Nerve</i> , 2001, 24, 963-965.	1.0	59
326	The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. <i>Clinical Endocrinology</i> , 2008, 69, 737-744.	1.2	59
327	Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders. <i>Gut</i> , 1994, 35, 1064-1069.	6.1	58
328	Treating irritable bowel syndrome: overview, perspective and future therapies. <i>British Journal of Pharmacology</i> , 2004, 141, 1237-1248.	2.7	58
329	Candidate genes and sensory functions in health and irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G219-G225.	1.6	58
330	Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 581-588.	1.9	58
331	Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 522-527.	2.4	57
332	A pilot study of motility and tone of the left colon in patients with diarrhea due to functional disorders and dysautonomia. <i>American Journal of Gastroenterology</i> , 1997, 92, 297-302.	0.2	57
333	Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls. <i>Gut</i> , 2002, 51, i34-i40.	6.1	56
334	Is There an Association Between GNP3-C825T Genotype and Lower Functional Gastrointestinal Disorders?. <i>Gastroenterology</i> , 2006, 130, 1985-1994.	0.6	56
335	Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. <i>Clinical Autonomic Research</i> , 2008, 18, 194-202.	1.4	56
336	Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G1262-G1269.	1.6	56
337	Improving the detection of environmental enteric dysfunction: a lactulose, rhamnose assay of intestinal permeability in children aged under 5 years exposed to poor sanitation and hygiene. <i>BMJ Global Health</i> , 2016, 1, e000066.	2.0	56
338	Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 1309-1319.e7.	0.6	56
339	Comprehensive assessment of gastric emptying with a stable isotope breath test. <i>Neurogastroenterology and Motility</i> , 2013, 25, e60-9.	1.6	55
340	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2018, 155, 168-179.	0.6	55
341	Mitochondrial neurogastrointestinal encephalomyopathy: Manometric and diagnostic features. <i>Gastroenterology</i> , 1999, 116, 959-963.	0.6	54
342	Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 869-878.	1.9	54

#	ARTICLE	IF	CITATIONS
343	Effect of Meal Ingestion on Ileocolonic and Colonic Transit in Health and Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2010, 55, 384-391.	1.1	54
344	Effects of Antidepressants on Gastric Function in Patients with Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2018, 113, 216-224.	0.2	54
345	Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes. <i>Diabetes</i> , 2001, 50, 565-572.	0.3	53
346	Mechanisms in IBS: something old, something new, something borrowed.... <i>Neurogastroenterology and Motility</i> , 2005, 17, 311-316.	1.6	53
347	Selection of electrical algorithms to treat obesity with intermittent vagal block using an implantable medical device. <i>Surgery for Obesity and Related Diseases</i> , 2009, 5, 224-229.	1.0	52
348	Scintigraphic Biomarkers for Colonic Dysmotility. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 748-753.	2.3	52
349	Neuropeptide S Receptor Induces Neuropeptide Expression and Associates With Intermediate Phenotypes of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2010, 138, 98-107.e4.	0.6	52
350	A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1088-1096.	1.9	52
351	RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, G1089-G1098.	1.6	52
352	Use of gastroduodenal manometry to differentiate mechanical and functional intestinal obstruction: an analysis of clinical outcome. <i>American Journal of Gastroenterology</i> , 1994, 89, 339-44.	0.2	51
353	Pharmacological modulation of rectal tone alters perception of distention in humans. <i>American Journal of Gastroenterology</i> , 1997, 92, 2073-9.	0.2	51
354	Effects of 5-HT ₃ antagonism on postprandial gastric volume and symptoms in humans. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 225-233.	1.9	50
355	Visceral Hypersensitivity. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S194-S203.	1.1	50
356	Effects of Amitriptyline on Gastric Sensorimotor Function and Postprandial Symptoms in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2008, 103, 2043-2050.	0.2	50
357	Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. <i>Journal of Gastroenterology</i> , 2013, 48, 177-181.	2.3	50
358	The SNMMI and EANM Practice Guideline for Small-Bowel and Colon Transit 1.0. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2004-2013.	2.8	50
359	Current Practice in the Diagnosis of Bile Acid Diarrhea. <i>Gastroenterology</i> , 2019, 156, 1233-1238.	0.6	50
360	Human Intestinal Barrier: Effects of Stressors, Diet, Prebiotics, and Probiotics. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00308.	1.3	50

#	ARTICLE	IF	CITATIONS
361	Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder. <i>Gastroenterology</i> , 1994, 106, 916-923.	0.6	49
362	The Role of Pelvic Floor Dysfunction and Slow Colonic Transit in Adolescents with Refractory Constipation. <i>American Journal of Gastroenterology</i> , 2004, 99, 1579-1584.	0.2	49
363	Review article: new receptor targets for medical therapy in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 35-46.	1.9	49
364	Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G553-G560.	1.6	49
365	Specific inhibition of bile acid transport alters plasma lipids and GLP-1. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 75.	0.7	49
366	Measurement of Gastrointestinal and Colonic Motor Functions in Humans and Animals. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 412-428.	2.3	49
367	Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13302.	1.6	49
368	Characterization of Upper Gastrointestinal Symptoms, Gastric Motor Functions, and Associations in Patients with Diabetes at a Referral Center. <i>American Journal of Gastroenterology</i> , 2019, 114, 143-154.	0.2	49
369	Chronic diarrhea: a review on pathophysiology and management for the clinical gastroenterologist. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 198-206.	2.4	48
370	Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1151-1160.	0.9	48
371	Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. <i>Neurogastroenterology and Motility</i> , 2015, 27, 324-332.	1.6	48
372	The Role of Bile Acids in Chronic Diarrhea. <i>American Journal of Gastroenterology</i> , 2020, 115, 1596-1603.	0.2	48
373	Brainstem tumor presenting as an upper gut motility disorder. <i>Gastroenterology</i> , 1985, 89, 1411-1414.	0.6	47
374	The effects of biofeedback on rectal sensation and distal colonic motility in patients with disorders of rectal evacuation Evidence of an inhibitory rectocolonic reflex in humans?. <i>American Journal of Gastroenterology</i> , 1999, 94, 751-756.	0.2	47
375	Performance characteristics of the measurement of gastric volume using single photon emission computed tomography. <i>Neurogastroenterology and Motility</i> , 2011, 23, 308-315.	1.6	47
376	Behavioral Intervention for the Treatment of Rumination. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1998, 27, 596-598.	0.9	47
377	Autonomic dysfunction in patients with chronic intestinal pseudo-obstruction. <i>Clinical Autonomic Research</i> , 1993, 3, 95-100.	1.4	46
378	Relationship of gastric emptying and volume changes after a solid meal in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, G261-G266.	1.6	46

#	ARTICLE	IF	CITATIONS
379	Validating biomarkers of treatable mechanisms in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1677-1685.	1.6	46
380	Is there a SERT-ain association with IBS?. <i>Gut</i> , 2004, 53, 1396-1399.	6.1	45
381	Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, G363-G369.	1.6	45
382	Obesity Does Not Increase Effects of Synthetic Ghrelin on Human Gastric Motor Functions. <i>Gastroenterology</i> , 2006, 131, 1431-1439.	0.6	45
383	High body mass alters colonic sensory-motor function and transit in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G382-G388.	1.6	45
384	Optimizing analysis of stable isotope breath tests to estimate gastric emptying of solids. <i>Neurogastroenterology and Motility</i> , 2009, 21, 706.	1.6	45
385	Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G508-G516.	1.6	45
386	Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. <i>Physiological Reports</i> , 2015, 3, e12610.	0.7	45
387	Epidemiology, Etiology, and Treatment of Gastroparesis: Real-World Evidence From a Large US National Claims Database. <i>Gastroenterology</i> , 2022, 162, 109-121.e5.	0.6	45
388	Does the nutrient drink test accurately predict postprandial gastric volume in health and community dyspepsia?. <i>Neurogastroenterology and Motility</i> , 2005, 17, 44-50.	1.6	44
389	Determination of gastric emptying in nonobese diabetic mice. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G1039-G1045.	1.6	44
390	Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G510-G516.	1.6	44
391	Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2011, 23, 995-e458.	1.6	44
392	Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G505-G510.	1.6	44
393	Clinical measurement of gastrointestinal motility and function: who, when and which test?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 568-579.	8.2	44
394	Neurohormonal factors in functional dyspepsia: insights on pathophysiological mechanisms. <i>Gastroenterology</i> , 1991, 100, 1311-8.	0.6	44
395	Pharmacological modulation of human gastric volumes demonstrated noninvasively using SPECT imaging. <i>Neurogastroenterology and Motility</i> , 2001, 13, 533-542.	1.6	43
396	A Controlled Pharmacogenetic Trial of Sibutramine on Weight Loss and Body Composition in Obese or Overweight Adults. <i>Gastroenterology</i> , 2008, 135, 1142-1154.	0.6	43

#	ARTICLE	IF	CITATIONS
397	<i>On the fiftieth anniversary</i> Postinfectious irritable bowel syndrome: mechanisms related to pathogens. <i>Neurogastroenterology and Motility</i> , 2014, 26, 156-167.	1.6	43
398	Effects of Clonidine in Women With Fecal Incontinence. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 843-851.e2.	2.4	43
399	Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression. <i>Laboratory Investigation</i> , 2017, 97, 14-23.	1.7	43
400	Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome—Diarrhea Without Bile Acid Malabsorption. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 720-727.e1.	2.4	43
401	Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. <i>EBioMedicine</i> , 2020, 55, 102759.	2.7	43
402	Coloanal motor coordination in association with high-amplitude colonic contractions after pharmacological stimulation. <i>American Journal of Gastroenterology</i> , 2000, 95, 715-719.	0.2	42
403	Enteric nervous system disorders: genetic and molecular insights for the neurogastroenterologist. <i>Neurogastroenterology and Motility</i> , 2001, 13, 277-295.	1.6	42
404	Behavioural and new pharmacological treatments for constipation: getting the balance right. <i>Gut</i> , 2010, 59, 1288-1296.	6.1	42
405	Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 44-59.	2.3	42
406	Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. <i>United European Gastroenterology Journal</i> , 2013, 1, 48-59.	1.6	42
407	Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride. <i>Neurogastroenterology and Motility</i> , 2015, 27, 397-405.	1.6	42
408	Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1705-1713.	1.6	42
409	¹³ C mannitol as a novel biomarker for measurement of intestinal permeability. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1114-1119.	1.6	42
410	Analysis of Fecal Primary Bile Acids Detects Increased Stool Weight and Colonic Transit in Patients With Chronic Functional Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 922-929.e2.	2.4	42
411	Medium term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. <i>Gut</i> , 1998, 42, 628-634.	6.1	41
412	Effects of asimadoline, a μ -opioid agonist, on satiation and postprandial symptoms in health. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 507-514.	1.9	41
413	Genetics and Genotypes in Irritable Bowel Syndrome: Implications for Diagnosis and Treatment. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 305-317.	1.0	41
414	Effect of the NK3receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. <i>Neurogastroenterology and Motility</i> , 2007, 19, 732-743.	1.6	41

#	ARTICLE	IF	CITATIONS
415	Current and novel therapeutic options for irritable bowel syndrome management. <i>Digestive and Liver Disease</i> , 2009, 41, 854-862.	0.4	41
416	LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. <i>Neurogastroenterology and Motility</i> , 2011, 23, 193-200.	1.6	41
417	Prevalence of colonic motor or evacuation disorders in patients presenting with chronic nausea and vomiting evaluated by a single gastroenterologist in a tertiary referral practice. <i>Neurogastroenterology and Motility</i> , 2014, 26, 131-138.	1.6	41
418	Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation. <i>American Journal of Gastroenterology</i> , 2016, 111, 1446-1454.	0.2	41
419	Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 303-316.	1.4	41
420	Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series. <i>Paediatric Drugs</i> , 2018, 20, 173-180.	1.3	41
421	Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis. <i>EClinicalMedicine</i> , 2021, 42, 101213.	3.2	41
422	Simplifying the evaluation of postprandial antral motor function in patients with suspected gastroparesis. <i>American Journal of Gastroenterology</i> , 1997, 92, 1496-500.	0.2	41
423	Influence of clinical parameters on the results of ¹³ C- α -octanoic acid breath tests: examination of different mathematical models in a large patient cohort. <i>Neurogastroenterology and Motility</i> , 2009, 21, 1039.	1.6	40
424	Role of prucalopride, a serotonin (5-HT ₄) receptor agonist, for the treatment of chronic constipation. <i>Clinical and Experimental Gastroenterology</i> , 2010, 3, 49.	1.0	40
425	Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis. <i>Neurogastroenterology and Motility</i> , 2011, 23, 935.	1.6	40
426	Six and 12 Weeks of Caloric Restriction Increases β Cell Function and Lowers Fasting and Postprandial Glucose Concentrations in People with Type 2 Diabetes. <i>Journal of Nutrition</i> , 2015, 145, 2046-2051.	1.3	40
427	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 24-41.e1.	2.4	40
428	Novel and Validated Approaches for Gastric Emptying Scintigraphy in Patients with Suspected Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1813-1815.	1.1	39
429	Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 818-828.	1.9	39
430	Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G10-G20.	1.6	39
431	Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2312-2319.e1.	2.4	39
432	Sex differences in NSAID-induced perturbation of human intestinal barrier function and microbiota. <i>FASEB Journal</i> , 2018, 32, 6615-6625.	0.2	39

#	ARTICLE	IF	CITATIONS
433	The current role of erythromycin in the clinical management of gastric emptying disorders. <i>American Journal of Gastroenterology</i> , 1993, 88, 169-71.	0.2	39
434	Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G120-G128.	1.6	38
435	Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1736-1746.	1.6	38
436	Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G442-G447.	1.6	38
437	Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases. <i>Current Opinion in Pharmacology</i> , 2017, 37, 80-86.	1.7	37
438	Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13313.	1.6	37
439	Gastroparesis. <i>Gastroenterology</i> , 2022, 162, 68-87.e1.	0.6	37
440	Rapid Gastric Emptying in Patients With Functional Diarrhea. <i>Mayo Clinic Proceedings</i> , 1997, 72, 323-328.	1.4	36
441	Anorexia nervosa: manifestations and management for the gastroenterologist. <i>American Journal of Gastroenterology</i> , 2002, 97, 255-269.	0.2	36
442	The effects of methylaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 884-893.	1.9	36
443	Current Medical Treatments of Dyspepsia and Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 481-493.	1.0	36
444	Guanylate Cyclase C Agonists: Emerging Gastrointestinal Therapies and Actions. <i>Gastroenterology</i> , 2015, 148, 483-487.	0.6	36
445	Effect of atilomotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study. <i>Neurogastroenterology and Motility</i> , 2006, 18, 28-36.	1.6	35
446	Randomised clinical trial: the effects of aikenchuto, <sc>TU</sc>â€100, on gastrointestinal and colonic transit, anorectal and bowel function in female patients with functional constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 776-785.	1.9	35
447	A meta-analysis of immunogenetic Case-Control Association Studies in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2015, 27, 717-727.	1.6	35
448	Combination Therapies for Obesity. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 390-394.	0.5	35
449	Appetite and obesity: a gastroenterologist's perspective. <i>Neurogastroenterology and Motility</i> , 2007, 19, 333-341.	1.6	34
450	An exploratory study of the association of adrenergic and serotonergic genotype and gastrointestinal motor functions. <i>Neurogastroenterology and Motility</i> , 2008, 20, 213-219.	1.6	34

#	ARTICLE	IF	CITATIONS
451	Intestinal Secretory Mechanisms in Irritable Bowel Syndrome—Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1051-1057.	2.4	34
452	Update on Bile Acid Malabsorption: Finally Ready for Prime Time?. <i>Current Gastroenterology Reports</i> , 2018, 20, 10.	1.1	34
453	What to do about the leaky gut. <i>Gut</i> , 2022, 71, 424-435.	6.1	34
454	Comparison of gastric volumes in response to isocaloric liquid and mixed meals in humans. <i>Neurogastroenterology and Motility</i> , 2004, 16, 567-573.	1.6	33
455	Pharmacological and Pharmacokinetic Aspects of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1421-1434.	0.6	33
456	Alteration of Gastric Functions and Candidate Genes Associated With Weight Reduction in Response to Sibutramine. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 829-837.	2.4	33
457	Comparison of simultaneous recordings of human colonic contractions by manometry and a barostat. <i>Neurogastroenterology and Motility</i> , 1994, 6, 213-222.	1.6	33
458	Selected Interventions in Nuclear Medicine: Gastrointestinal Motor Functions. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 186-194.	2.5	33
459	Gastric Antral Injections of Botulinum Toxin Delay Gastric Emptying but Do Not Reduce Body Weight. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 145-150.e1.	2.4	33
460	Effects of hemin on heme oxygenase-1, gastric emptying, and symptoms in diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1731-1740.	1.6	33
461	Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function. <i>American Journal of Gastroenterology</i> , 2017, 112, 913-923.	0.2	33
462	Pharmacotherapy for Irritable Bowel Syndrome. <i>Journal of Clinical Medicine</i> , 2017, 6, 101.	1.0	33
463	Etiopathogenetic Mechanisms in Diverticular Disease of the Colon. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 15-32.	2.3	33
464	Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. <i>Gastroenterology</i> , 2020, 158, 786-788.e1.	0.6	33
465	Sex as a biological variable in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13802.	1.6	33
466	The gastrointestinal tract and glucose tolerance. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2004, 7, 479-484.	1.3	32
467	Elobixibat for the treatment of constipation. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 277-284.	1.9	32
468	Genetics of human gastrointestinal sensation. <i>Neurogastroenterology and Motility</i> , 2013, 25, 458-466.	1.6	32

#	ARTICLE	IF	CITATIONS
469	Novel association of rectal evacuation disorder and rumination syndrome: Diagnosis, comorbidities, and treatment. <i>United European Gastroenterology Journal</i> , 2014, 2, 38-46.	1.6	32
470	Reproducibility of gastric emptying assessed with scintigraphy in patients with upper GI symptoms. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13365.	1.6	32
471	Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 744-758.	1.9	32
472	Review article: clinical evidence to support current therapies of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 48-53.	1.9	31
473	Feasibility and Application of 3D Ultrasound for Measurement of Gastric Volumes in Healthy Adults and Adolescents. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 48, 287-293.	0.9	31
474	Increased Nutrient Sensitivity and Plasma Concentrations of Enteral Hormones During Duodenal Nutrient Infusion in Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2014, 109, 1910-1920.	0.2	31
475	Gastrointestinal morbidity in obesity. <i>Annals of the New York Academy of Sciences</i> , 2014, 1311, 42-56.	1.8	31
476	Actionable biomarkers: the key to resolving disorders of gastrointestinal function. <i>Gut</i> , 2020, 69, 1730-1737.	6.1	31
477	New Developments in Prokinetic Therapy for Gastric Motility Disorders. <i>Frontiers in Pharmacology</i> , 2021, 12, 711500.	1.6	31
478	Managing Conflict of Interest in Clinical Practice. <i>Mayo Clinic Proceedings</i> , 2007, 82, 607-614.	1.4	30
479	Pharmacogenetics of the Effects of Colesevelam on Colonic Transit in Irritable Bowel Syndrome with Diarrhea. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1222-1226.	1.1	30
480	Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, G13-G26.	1.6	30
481	The Gastrointestinal Tract as an Integrator of Mechanical and Hormonal Response to Nutrient Ingestion. <i>Diabetes</i> , 2017, 66, 2729-2737.	0.3	30
482	Exploring hypotheses and rationale for causes of infantile colic. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12943.	1.6	30
483	Presence of intraepithelial food antigen in patients with active eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 427-433.	1.9	30
484	Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 808-820.	1.9	30
485	Genetics and Irritable Bowel Syndrome: From Genomics to Intermediate Phenotype and Pharmacogenetics. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2318-2324.	1.1	29
486	Clinical Features and Colonic Motor Disturbances in Chronic Megacolon in Adults. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2398-2407.	1.1	29

#	ARTICLE	IF	CITATIONS
487	Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G777-G784.	1.6	29
488	Open: Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial. <i>American Journal of Gastroenterology</i> , 2018, 113, 725-734.	0.2	29
489	The Effects of Biofeedback on Rectal Sensation and Distal Colonic Motility in Patients With Disorders of Rectal Evacuation. <i>American Journal of Gastroenterology</i> , 1999, 94, 751-756.	0.2	28
490	Pharmacology and clinical experience with alosetron. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 147-159.	1.9	28
491	New imaging in neurogastroenterology: an overview. <i>Neurogastroenterology and Motility</i> , 2006, 18, 805-812.	1.6	28
492	Effect of different macronutrients in excess on gastric sensory and motor functions and appetite in normal-weight, overweight, and obese humans. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 411-418.	2.2	28
493	Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?. <i>Neurogastroenterology and Motility</i> , 2007, 19, 77-84.	1.6	28
494	Dose-response effect of a β_2 -adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, G1114-G1119.	1.6	28
495	Perspective: Conflict of Interest and Professional Organizations: Considerations and Recommendations. <i>Academic Medicine</i> , 2010, 85, 85-91.	0.8	28
496	Prucalopride for constipation. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 451-461.	0.9	28
497	What are the important subsets of gastroparesis?. <i>Neurogastroenterology and Motility</i> , 2012, 24, 597-603.	1.6	28
498	Enteroendocrine and Neuronal Mechanisms in Pathophysiology of Acute Infectious Diarrhea. <i>Digestive Diseases and Sciences</i> , 2012, 57, 19-27.	1.1	28
499	Elobixibat for the treatment of constipation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 951-960.	1.4	28
500	Combined Fasting Serum C4 and Primary Bile Acids From a Single Stool Sample to Diagnose Bile Acid Diarrhea. <i>Gastroenterology</i> , 2020, 159, 1952-1954.e2.	0.6	28
501	Dose-related effects of synthetic human beta-endorphin and naloxone on fed gastrointestinal motility. <i>American Journal of Physiology - Renal Physiology</i> , 1986, 251, G147-G154.	1.6	27
502	Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans. <i>Neurogastroenterology and Motility</i> , 2004, 16, 729-735.	1.6	27
503	The Con Argument. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 129-132.	2.4	27
504	Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial. <i>Digestive Diseases and Sciences</i> , 2016, 61, 852-860.	1.1	27

#	ARTICLE	IF	CITATIONS
505	Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , 2016, 40, 1089-1095.	1.3	27
506	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. <i>Gut</i> , 2018, 67, 1425-1433.	6.1	27
507	Review article: biological mechanisms for symptom causation by individual FODMAP subgroups – the case for a more personalised approach to dietary restriction. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 517-529.	1.9	27
508	Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13571.	1.6	27
509	Audit of the diagnosis of rectal evacuation disorders in chronic constipation. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13510.	1.6	27
510	Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2962-2970.e6.	2.4	27
511	Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. <i>Journal of Clinical Investigation</i> , 2013, 123, 4111-4120.	3.9	27
512	Advances in diabetic gastroparesis. <i>Reviews in Gastroenterological Disorders</i> , 2002, 2, 47-56.	0.6	27
513	Pseudodominant Transmission of Fructose Intolerance in an Adult and Three Offspring. <i>New England Journal of Medicine</i> , 1982, 307, 537-540.	13.9	26
514	Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1122-1131.	1.9	26
515	Linacotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 301-310.	1.4	26
516	925g Plecanatide, a Novel Guanylate Cyclase-C (GC-C) Receptor Agonist, is Efficacious and Safe in Patients with Chronic Idiopathic Constipation (CIC): Results from a 951 Patient, 12 Week, Multi-Center Trial. <i>Gastroenterology</i> , 2013, 144, S-163.	0.6	26
517	Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1341-1348.	1.6	26
518	Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2016, 150, 1319-1331.e20.	0.6	26
519	Gastrointestinal traits: individualizing therapy for obesity with drugs and devices. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 48-56.	0.5	26
520	Rectal Gas Volume Measured by Computerized Tomography Identifies Evacuation Disorders in Patients With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 543-552.e4.	2.4	26
521	Malignancy and Meckel's diverticulum: A systematic literature review and 14-year experience at a tertiary referral center. <i>United European Gastroenterology Journal</i> , 2018, 6, 739-747.	1.6	26
522	Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1139-1148.	1.9	26

#	ARTICLE	IF	CITATIONS
523	Pharmacological inhibition of chenodeoxycholate-induced fluid and mucus secretion and mucosal injury in the rabbit colon. <i>Digestive Diseases and Sciences</i> , 1982, 27, 865-869.	1.1	25
524	Familial enteric neuropathy with pseudoobstruction. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1168-1171.	1.1	25
525	Motilin agonists and dyspepsia: throwing out the baby with the bath water. <i>Gut</i> , 2002, 51, 612-613.	6.1	25
526	Probiotics and Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, S123-S125.	1.1	25
527	Pharmacogenetics of low dose clonidine in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2009, 21, 399-410.	1.6	25
528	A Randomized Trial of 5-Hydroxytryptamine ₄ Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 701-708.e1.	2.4	25
529	Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G365-G376.	1.6	25
530	Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. <i>Handbook of Experimental Pharmacology</i> , 2016, 239, 75-113.	0.9	25
531	Bile acid disease. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 189-195.	1.0	25
532	Secretory diarrhea and hypokalemia associated with colonic pseudoobstruction: A case study and systematic analysis of the literature. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13120.	1.6	25
533	Nitrgergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, G1359-G1365.	1.6	24
534	Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome. <i>Physiological Reports</i> , 2017, 5, e13170.	0.7	24
535	Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 398-406.	1.8	24
536	Comparison of pH and motility of the small intestine of healthy subjects and patients with symptomatic constipation using the wireless motility capsule. <i>International Journal of Pharmaceutics</i> , 2018, 544, 158-164.	2.6	24
537	Development and Validation of Test for "Leaky Gut" Small Intestinal and Colonic Permeability Using Sugars in Healthy Adults. <i>Gastroenterology</i> , 2021, 161, 463-475.e13.	0.6	24
538	Stasis syndromes following gastric surgery: clinical and motility features of 60 symptomatic patients. <i>Journal of Clinical Gastroenterology</i> , 1990, 12, 505-12.	1.1	24
539	Appraisal of medium- and long-term treatment of gastroparesis and chronic intestinal dysmotility. <i>American Journal of Gastroenterology</i> , 1994, 89, 1769-74.	0.2	24
540	Hyperventilation alters colonic motor and sensory function: Effects and mechanisms in humans. <i>Gastroenterology</i> , 1996, 111, 368-377.	0.6	23

#	ARTICLE	IF	CITATIONS
541	Diagnosis and treatment of enteric neuromuscular diseases. <i>Clinical Autonomic Research</i> , 2003, 13, 10-15.	1.4	23
542	Effects of Desipramine and Escitalopram on Postprandial Symptoms Induced by the Nutrient Drink Test in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Digestion</i> , 2005, 72, 97-103.	1.2	23
543	Functional Dyspepsia: Mechanisms of Symptom Generation and Appropriate Management of Patients. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 649-664.	1.0	23
544	Developing Irritable Bowel Syndrome Guidelines Through Meta-analyses: Does the Emperor Really Have New Clothes?. <i>Gastroenterology</i> , 2009, 137, 766-769.	0.6	23
545	Gastric Emptying. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 823-827.	2.4	23
546	Validation of a Bowel Function Diary for Assessing Opioid-Induced Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 497-506.	0.2	23
547	Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 769-779.	1.9	23
548	The role of peptide YY in integrative gut physiology and potential role in obesity. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007, 14, 52-57.	1.2	22
549	Characteristics of chronic megacolon among patients diagnosed with multiple endocrine neoplasia type 2B. <i>United European Gastroenterology Journal</i> , 2016, 4, 449-454.	1.6	22
550	Upper gastrointestinal complications following ablation therapy for atrial fibrillation. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13109.	1.6	22
551	Relamorelin for the treatment of gastrointestinal motility disorders. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1189-1197.	1.9	22
552	Use of prucalopride in adults with chronic idiopathic constipation. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 579-589.	1.3	22
553	Aquaporin Expression in Colonic Mucosal Biopsies From Irritable Bowel Syndrome With Diarrhea. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00019.	1.3	22
554	Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility.. <i>Alimentary Pharmacology and Therapeutics</i> , 1996, 10, 403-409.	1.9	21
555	Motor Function in Irritable Bowel Syndrome. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1999, 13, 8A-11A.	1.8	21
556	Principles and Process in the Development of the Mayo Clinic's Individual and Institutional Conflict of Interest Policy. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1340-1346.	1.4	21
557	Double-blind, randomized, placebo-controlled study to evaluate the effects of tegaserod on gastric motor, sensory and myoelectric function in healthy volunteers. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 859-867.	1.9	21
558	Effects of an osmotically active agent on colonic transit.. <i>Neurogastroenterology and Motility</i> , 2006, 18, 300-306.	1.6	21

#	ARTICLE	IF	CITATIONS
559	Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT ₄ agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. <i>Neurogastroenterology and Motility</i> , 2007, 19, 821-830.	1.6	21
560	Evolving Concepts of the Pathogenesis of Irritable Bowel Syndrome: To Treat the Brain or the Gut?. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2009, 48, S46-8.	0.9	21
561	Emerging Pharmacologic Therapies for Irritable Bowel Syndrome. <i>Current Gastroenterology Reports</i> , 2010, 12, 408-416.	1.1	21
562	Pharmacodynamic and Clinical Endpoints for Functional Colonic Disorders: Statistical Considerations. <i>Digestive Diseases and Sciences</i> , 2012, 58, 509-18.	1.1	21
563	929a A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 in Patients with Diabetic Gastroparesis. <i>Gastroenterology</i> , 2014, 146, S-158-S-159.	0.6	21
564	Fecal Bile Acid Testing in Assessing Patients With Chronic Unexplained Diarrhea: Implications for Healthcare Utilization. <i>American Journal of Gastroenterology</i> , 2020, 115, 1094-1102.	0.2	21
565	Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications. <i>Nutrients</i> , 2021, 13, 1158.	1.7	21
566	Randomised study: effects of the 5-HT ₄ receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1010-1020.	1.9	21
567	Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy. <i>World Journal of Gastroenterology</i> , 2019, 25, 1185-1196.	1.4	21
568	Ascending Colon Response to Feeding: Evidence for a 5-Hydroxytryptamine-3 Mechanism. <i>Scandinavian Journal of Gastroenterology</i> , 1995, 30, 562-567.	0.6	20
569	Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease. <i>Gut</i> , 2011, 60, 425-428.	6.1	20
570	Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC ₄) by mass spectrometry. <i>Clinical Biochemistry</i> , 2018, 52, 106-111.	0.8	20
571	Pretest and Post-test Probabilities of Diagnoses of Rectal Evacuation Disorders Based on Symptoms, Rectal Exam, and Basic Tests: a Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2479-2490.	2.4	20
572	Impact of Bile Acid Diarrhea in Patients With Diarrhea-Predominant Irritable Bowel Syndrome on Symptoms and Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2083-2090.e1.	2.4	20
573	Management of patients with chronic abdominal pain in clinical practice. <i>Neurogastroenterology and Motility</i> , 2006, 18, 499-506.	1.6	19
574	The Relationship Between Clinical Factors and Gastrointestinal Dysmotility in Diabetes Mellitus. <i>Neurogastroenterology and Motility</i> , 1991, 3, 268-272.	1.6	19
575	Peripheral mechanisms in the control of appetite and related experimental therapies in obesity. <i>Regulatory Peptides</i> , 2009, 156, 24-27.	1.9	19
576	Reproducibility and Performance Characteristics of Colonic Compliance, Tone, and Sensory Tests in Healthy Humans. <i>Digestive Diseases and Sciences</i> , 2010, 55, 709-715.	1.1	19

#	ARTICLE	IF	CITATIONS
577	Association of <i>TCF7L2</i> Allelic Variations with Gastric Function, Satiation, and GLP-1 Levels. <i>Clinical and Translational Science</i> , 2011, 4, 183-187.	1.5	19
578	Effects of Amitriptyline and Escitalopram on Sleep and Mood in Patients With Functional Dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 401-406.e2.	2.4	19
579	Gastric accommodation measurements by single photon emission computed tomography and two-dimensional scintigraphy in diabetic patients with upper gastrointestinal symptoms. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13581.	1.6	19
580	Colonic Manifestations and Complications Are Relatively Under-Reported in Systemic Sclerosis: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2019, 114, 1847-1856.	0.2	19
581	The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 821-828.	1.9	19
582	Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1748-1758.e2.	2.4	19
583	Irritable Bowel Syndrome: Straightening the road from the Rome criteria. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13957.	1.6	19
584	Food Residue During Esophagogastroduodenoscopy Is Commonly Encountered and Is Not Pathognomonic of Delayed Gastric Emptying. <i>Digestive Diseases and Sciences</i> , 2020, 66, 3951-3959.	1.1	19
585	Gender differences in irritable bowel syndrome. <i>Journal of Gender-specific Medicine</i> , 2002, 5, 37-45.	0.1	19
586	Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1037-1043.	1.9	18
587	Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans. <i>Neurogastroenterology and Motility</i> , 2007, 19, 716-723.	1.6	18
588	Lubiprostone for the treatment of opioid-induced bowel dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 983-990.	0.9	18
589	A ghrelin agonist fails to show benefit in patients with diabetic gastroparesis: let's not throw the baby out with the bath water. <i>Neurogastroenterology and Motility</i> , 2013, 25, 859-863.	1.6	18
590	Interpretation of overall colonic transit in defecation disorders in males and females. <i>Neurogastroenterology and Motility</i> , 2013, 25, 502.	1.6	18
591	Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 336-338.	2.4	18
592	Targeting neurons in the gastrointestinal tract to treat Parkinson's disease. <i>Clinical Parkinsonism & Related Disorders</i> , 2019, 1, 2-7.	0.5	18
593	Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 37-53.	1.9	18
594	What is the leaky gut? Clinical considerations in humans. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 473-482.	1.3	18

#	ARTICLE	IF	CITATIONS
595	Bile acid detergency: permeability, inflammation, and effects of sulfation. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 322, G480-G488.	1.6	18
596	HLA-DQ genotype is associated with accelerated small bowel transit in patients with diarrhea-predominant irritable bowel syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 481-487.	0.8	17
597	Comparison of mucosal impedance measurements throughout the esophagus and mucosal eosinophil counts in endoscopic biopsy specimens in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 693-700.e1.	0.5	17
598	Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1179-1192.	1.9	17
599	Pharmacogenomics and functional gastrointestinal disorders. <i>Pharmacogenomics</i> , 2005, 6, 491-501.	0.6	16
600	Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications. <i>Neurogastroenterology and Motility</i> , 2007, 19, 40-45.	1.6	16
601	Comparison of mathematical methods for calculating colonic compliance in humans: power exponential, computer-based and manual linear interpolation models. <i>Neurogastroenterology and Motility</i> , 2008, 20, 330-335.	1.6	16
602	Association of melanocortin 4 receptor gene variation with satiation and gastric emptying in overweight and obese adults. <i>Genes and Nutrition</i> , 2014, 9, 384.	1.2	16
603	Novel therapeutic agents in neurogastroenterology: advances in the past year. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1070-1078.	1.6	16
604	A single-center, prospective, double-blind, sham-controlled, randomized study of the effect of a vibrating capsule on colonic transit in patients with chronic constipation. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13034.	1.6	16
605	GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1967-1977.	1.8	16
606	Chronic Megacolon Presenting in Adolescents or Adults: Clinical Manifestations, Diagnosis, and Genetic Associations. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2750-2756.	1.1	16
607	Association between gastrointestinal phenotypes and weight gain in younger adults: a prospective 4-year cohort study. <i>International Journal of Obesity</i> , 2020, 44, 2472-2478.	1.6	16
608	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, e10-e27.	0.1	16
609	Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. <i>International Journal of Obesity</i> , 2022, 46, 555-563.	1.6	16
610	Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. <i>American Journal of Gastroenterology</i> , 1997, 92, 2250-6.	0.2	16
611	Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2023, 72, 54-65.	6.1	16
612	A Preliminary Candidate Genotype-Intermediate Phenotype Study of Satiation and Gastric Motor Function in Obesity. <i>Obesity</i> , 2010, 18, 1201-1211.	1.5	15

#	ARTICLE	IF	CITATIONS
613	Comparison of calculations to estimate gastric emptying half-time of solids in humans. <i>Neurogastroenterology and Motility</i> , 2012, 24, 1142-1145.	1.6	15
614	Re: Halmos et al, A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2014, 146, 1829-1830.	0.6	15
615	Toward an effective peripheral visceral analgesic: responding to the national opioid crisis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G637-G646.	1.6	15
616	Hirschsprung disease: Insights on genes, penetrance, and prenatal diagnosis. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13732.	1.6	15
617	Gastric accommodation influences proximal gastric and total gastric emptying in concurrent measurements conducted in healthy volunteers. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G759-G767.	1.6	15
618	Bile Acid Diarrhea in Adults and Adolescents. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14287.	1.6	15
619	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. <i>Cell Genomics</i> , 2021, 1, 100069.	3.0	15
620	Effects of Heterozygous Variants in the Leptin-Melanocortin Pathway on Roux-en-Y Gastric Bypass Outcomes: a 15-Year Case-Control Study. <i>Obesity Surgery</i> , 2022, 32, 2632-2640.	1.1	15
621	Ten secrets for development of drugs for functional gastrointestinal diseases. <i>Gastroenterology</i> , 2000, 118, 653.	0.6	14
622	Is there a role for probiotics in irritable bowel syndrome?. <i>Digestive and Liver Disease</i> , 2006, 38, S266-S269.	0.4	14
623	Challenges in drug development for functional gastrointestinal disorders. Part II: Visceral pain. <i>Neurogastroenterology and Motility</i> , 2006, 18, 354-360.	1.6	14
624	Pharmacogenetics: potential role in the treatment of diabetes and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1109-1119.	0.9	14
625	Effect of the $\alpha 2\delta$ ligand, pregabalin, on colonic sensory and motor functions in healthy adults. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G377-G384.	1.6	14
626	Small intestinal permeability in patients with eosinophilic oesophagitis during active phase and remission. <i>Gut</i> , 2015, 64, 538-543.	6.1	14
627	Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13686.	1.6	14
628	The American neurogastroenterology and motility society gastroparesis cardinal symptom index-daily diary (ANMS GCSI-DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13553.	1.6	14
629	Opiates, the Pylorus, and Gastroparesis. <i>Gastroenterology</i> , 2020, 159, 414-421.	0.6	14
630	Review article: Elobixibat: a novel treatment for chronic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 234-242.	1.9	14

#	ARTICLE	IF	CITATIONS
631	What's in a name? Roll on Rome II. <i>Gastroenterology</i> , 1998, 114, 237.	0.6	13
632	Reliability of a semi-automated analysis to measure gastric accommodation using SPECT in humans. <i>Gastroenterology</i> , 2001, 120, A287.	0.6	13
633	Stomach Dysfunction in Diabetes Mellitus: Emerging Technology and Pharmacology. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 180-189.	1.3	13
634	Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity. <i>Neurogastroenterology and Motility</i> , 2011, 23, 637-e257.	1.6	13
635	Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D ₂ /D ₃ receptor antagonist, in patients with gastroparesis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 267-280.	1.9	13
636	Association of gastric emptying with postprandial appetite and satiety sensations in obesity. <i>Obesity</i> , 2021, 29, 1497-1507.	1.5	13
637	Acute and chronic intestinal pseudo-obstruction. <i>Advances in Internal Medicine</i> , 1991, 36, 287-306.	0.9	13
638	Does delayed gastric emptying really cause symptoms in functional dyspepsia?. <i>Gut</i> , 2006, 55, 909-910.	6.1	12
639	Editorial: Is Adequate Relief Fatally Flawed or Adequate as an End Point in Irritable Bowel Syndrome?. <i>American Journal of Gastroenterology</i> , 2009, 104, 920-922.	0.2	12
640	Proximal and Overall Gastric Emptying of Solids in Patients with Reduced Gastric Volume Accommodation Compared to Matched Controls. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1729-1734.	1.1	12
641	The role of pharmacogenetics in nonmalignant gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 173-184.	8.2	12
642	POEMs for gastroparesis. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 129-131.	0.5	12
643	Effects of naloxegol on whole gut transit in opioid-naïve healthy subjects receiving codeine: A randomized, controlled trial. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13298.	1.6	12
644	The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 61.	0.9	12
645	It ain't over 'till it's over! Risk mitigation strategies for patients with gastrointestinal diseases in the aftermath of the COVID-19 pandemic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1117-1123.	1.4	12
646	The ileocecal Area and the Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 1991, 20, 297-311.	1.0	12
647	Pathophysiology in irritable bowel syndrome. <i>Drug News and Perspectives</i> , 2001, 14, 268.	1.9	12
648	The Stomach in Diabetes: From Villain to Ally. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 285-287.	2.4	11

#	ARTICLE	IF	CITATIONS
649	Do the Symptom-Based, Rome Criteria of Irritable Bowel Syndrome Lead to Better Diagnosis and Treatment Outcomes?. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 125.	2.4	11
650	Inclusion criteria for pharmacodynamic and clinical trials in chronic idiopathic constipation: pitfalls in using Rome III for functional constipation. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 159-163.	1.4	11
651	Ramosetron in Irritable Bowel Syndrome With Diarrhea: New Hope or the Same Old Story?. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 960-962.	2.4	11
652	Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS. <i>United European Gastroenterology Journal</i> , 2015, 3, 53-62.	1.6	11
653	Evaluating the safety and the effects on colonic compliance of neostigmine during motility testing in patients with chronic constipation. <i>Neurogastroenterology and Motility</i> , 2016, 28, 871-878.	1.6	11
654	Polymorphisms of 5-HTT LPR and GN ²³ 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial. <i>American Journal of Gastroenterology</i> , 2017, 112, 903-909.	0.2	11
655	Disorders of small intestinal motility. <i>Gastroenterology Clinics of North America</i> , 1989, 18, 405-24.	1.0	11
656	A patient with localized megacolon and intractable constipation: evidence for impairment of colonic muscle tone. <i>American Journal of Gastroenterology</i> , 1994, 89, 1867-70.	0.2	11
657	Antral axial forces postprandially and after erythromycin in organic and functional dysmotilities. <i>Digestive Diseases and Sciences</i> , 1996, 41, 697-704.	1.1	10
658	Drugs targeting functional bowel disorders: lessons from drug trials. <i>Current Opinion in Pharmacology</i> , 2002, 2, 684-690.	1.7	10
659	GI clinical research 2002-2003: the year in review. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 415-420.	2.4	10
660	New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 29B-35B.	1.8	10
661	Editorial: Fecal Granins in IBS: Cause or Indicator of Intestinal or Colonic Irritation?. <i>American Journal of Gastroenterology</i> , 2012, 107, 448-450.	0.2	10
662	Rectal gas volume: Defining cutoffs for screening for evacuation disorders in patients with constipation. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13044.	1.6	10
663	Insights on Obesity in Children and Adults: Individualizing Management. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 724-734.	3.1	10
664	Evaluation of Patients with Suspected Gastroparesis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 39-54.	0.6	10
665	Clinical Features and Associations of Descending Perineum Syndrome in 300 Adults with Constipation in Gastroenterology Referral Practice. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3688-3695.	1.1	10
666	Physical activity is associated with accelerated gastric emptying and increased ghrelin in obesity. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13879.	1.6	10

#	ARTICLE	IF	CITATIONS
667	A smart toilet for personalized health monitoring. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 453-454.	8.2	10
668	Refractory Constipation. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 623-642.	1.0	10
669	Â²Â ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?. <i>Gut</i> , 2007, 56, 1337-1338.	6.1	9
670	Irritable bowel syndrome: how useful is the term and the "diagnosis"?. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 381-386.	1.4	9
671	Simplifying the measurement of gastric accommodation using <scp>SPECT</scp>. <i>Neurogastroenterology and Motility</i> , 2013, 25, 542-546.	1.6	9
672	The effect of vagal nerve blockade using electrical impulses on glucose metabolism in nondiabetic subjects. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 305.	1.1	9
673	Expanding criteria for slow colonic transit in patients being evaluated for chronic constipation by scintigraphy. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13878.	1.6	9
674	Treating the pylorus in gastroparesis: The new riddle wrapped in the ultimate enigma?. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 1300-1302.	0.5	9
675	Cohort Study in Parkinsonism. <i>Neurology: Clinical Practice</i> , 2021, 11, e407-e413.	0.8	9
676	Severity of dysphagia is associated with hospitalizations and mortality in patients with Parkinson's disease. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14280.	1.6	9
677	Relation between fat malabsorption and transit abnormalities in human carcinoid diarrhea. <i>Gastroenterology</i> , 1996, 110, 405-410.	0.6	8
678	Effect of Somatostatin Analog on Postprandial Satiety in Obesity. <i>Obesity</i> , 2005, 13, 1572-1579.	4.0	8
679	A Twenty-one-Year-Old College Student With Postprandial Regurgitation and Weight Loss. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1314-1317.	2.4	8
680	Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 306-320.	2.3	8
681	American college of gastroenterology monograph on the management of irritable bowel syndrome. Expert Opinion on Pharmacotherapy, 2015, 16, 629-632.	0.9	8
682	New and Investigational Agents for Irritable Bowel Syndrome. <i>Current Gastroenterology Reports</i> , 2015, 17, 46.	1.1	8
683	Drug-resin drug interactions in patients with delayed gastric emptying: What is optimal time window for drug administration?. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1268-1271.	1.6	8
684	Enhancing High Value Care in Gastroenterology Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1376-1384.	2.4	8

#	ARTICLE	IF	CITATIONS
685	Regional Colonic Transit Pattern Does Not Conclusively Identify Evacuation Disorders in Constipated Patients with Delayed Colonic Transit. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 92-100.	0.8	8
686	Whatâ€™s in the pipeline for lower functional gastrointestinal disorders in the next 5 years?. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G640-G650.	1.6	8
687	Familial chronic megacolon presenting in childhood or adulthood: Seeking the presumed gene association. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13550.	1.6	8
688	Markers of Bile Acid Metabolism in Pediatric Diarrhea Predominant Irritable Bowel Syndrome and Healthy Controls. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 859-865.	0.9	8
689	Secretin effects on gastric functions, hormones and symptoms in functional dyspepsia and health: randomized crossover trial. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G635-G645.	1.6	8
690	Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 110-122.	4.0	8
691	Fasting pyloric diameter and distensibility by functional endoluminal imaging probe in unsedated healthy volunteers. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14386.	1.6	8
692	Opiates in the control of gastrointestinal tract function: current knowledge and new avenues for research. <i>Neurogastroenterology and Motility</i> , 2004, 16, 67-70.	1.6	7
693	Clinical application of pharmacogenetics in gastrointestinal diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1857-1869.	0.9	7
694	Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. <i>Neurogastroenterology and Motility</i> , 2008, 20, 891-899.	1.6	7
695	Pharmacogenomics in Gastrointestinal Disorders. <i>Methods in Molecular Biology</i> , 2008, 448, 395-412.	0.4	7
696	Sa2051 A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RM-131 in Patients With Chronic Constipation. <i>Gastroenterology</i> , 2014, 146, S-364.	0.6	7
697	A Pilot Study of the Effect of Daikenchuto on Rectal Sensation in Patients with Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 22, 69-77.	0.8	7
698	Editorial: Dissecting Molecular Mechanisms in Bile Acid Diarrhea. <i>American Journal of Gastroenterology</i> , 2016, 111, 433-435.	0.2	7
699	Opioid analgesic use among patients presenting with acute abdominal pain and factors associated with surgical diagnoses. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13000.	1.6	7
700	A working paradigm for the treatment of obesity in gastrointestinal practice. <i>Techniques in Gastrointestinal Endoscopy</i> , 2017, 19, 52-60.	0.3	7
701	Relamorelin in Patients with Diabetic Gastroparesis: Efficacy and Safety Results from a Phase 2B Randomized, Double-Blind, Placebo-Controlled, 12-Week Study (RM-131-009). <i>Gastroenterology</i> , 2017, 152, S139-S140.	0.6	7
702	Breath Testing Consensus Guidelines for SIBO: RES IPSA LOCQUITOR. <i>American Journal of Gastroenterology</i> , 2017, 112, 1888-1889.	0.2	7

#	ARTICLE	IF	CITATIONS
703	Implications of Pharmacogenomics to the Management of IBS. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 584-594.	2.4	7
704	Associations of gastric volumes, ingestive behavior, calorie and volume intake, and fullness in obesity. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G238-G244.	1.6	7
705	FMT in IBS: a call for caution. <i>Gut</i> , 2021, 70, gutjnl-2020-321529.	6.1	7
706	Selecting optimal patients with gastroparesis for G-POEM procedure. <i>Gut</i> , 2022, 71, 659-660.	6.1	7
707	Increased Fecal Bile Acid Excretion in a Significant Subset of Patients with Other Inflammatory Diarrheal Diseases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2413-2419.	1.1	7
708	Relationship of motor mechanisms to gastroparesis symptoms: toward individualized treatment. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G558-G563.	1.6	7
709	Review : Noninvasive Measurement of Gastric Accommodation by SPECT. <i>Korean Journal of Internal Medicine</i> , 2002, 17, 1-6.	0.7	7
710	Gastrointestinal motility disorders in patients with multiple sclerosis: A single-center study. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14326.	1.6	7
711	2021 Workshop: Neurodegenerative Diseases in the Gut-Brain Axis—Parkinson's Disease. <i>Gastroenterology</i> , 2022, 162, 1574-1582.	0.6	7
712	Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	1.4	7
713	Pain in irritable bowel syndrome: Does anything really help?. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14305.	1.6	7
714	Comprehensive characterization of antral and pyloric contractions by high resolution manometry: applied physiology in suspected gastroparesis. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, G255-G264.	1.6	7
715	Audit of the Treatment of Malnutrition Due to Chronic Intestinal Pseudo-Obstruction With Enteral Nutrition. <i>Nutrition in Clinical Practice</i> , 1999, 14, 29-32.	1.1	6
716	T1405 Effects of a Novel Corticotrophin Releasing Factor Receptor-1 Antagonist, BMS-562086, On Gastrointestinal and Colonic Transit and Bowel Habits in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS). <i>Gastroenterology</i> , 2008, 134, A-548.	0.6	6
717	T1402 Efficacy of 12-Week Treatment with Prucalopride (Resolor®) in Patients with Chronic Constipation: Combined Results of Three Identical Randomized, Double-Blind, Placebo-Controlled Phase III Trials. <i>Gastroenterology</i> , 2008, 134, A-548.	0.6	6
718	Association of <i>UCP3</i> rs1626521 with obesity and stomach functions in humans. <i>Obesity</i> , 2015, 23, 898-906.	1.5	6
719	A North American perspective on the ESNM consensus statement on gastroparesis. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14174.	1.6	6
720	Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies. <i>Journal of Pain Research</i> , 2021, Volume 14, 2179-2189.	0.8	6

#	ARTICLE	IF	CITATIONS
721	Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 855-863.	2.4	6
722	Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial. <i>JGH Open</i> , 2021, 5, 193-198.	0.7	6
723	The ileocecal area and the irritable bowel syndrome. <i>Gastroenterology Clinics of North America</i> , 1991, 20, 297-311.	1.0	6
724	Differential mRNA expression in ileal and colonic biopsies in irritable bowel syndrome with diarrhea or constipation. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, G88-G101.	1.6	6
725	Recombinant human neurotrophin-3 increases noncholinergic smooth muscle contractility and decreases nonadrenergic noncholinergic (NANC) inhibition of myenteric neurons in guinea-pig colon. <i>Gastroenterology</i> , 2000, 118, A710.	0.6	5
726	Advances in Pharmacological Treatments of IBS. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2004, 39, S766-S767.	0.9	5
727	Conflicts of Interest and Disclosures in Publications. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 268-273.e1.	2.4	5
728	Drug development and IBS drugs: experience from the past, current challenges, and proposal for the future. <i>Current Opinion in Pharmacology</i> , 2008, 8, 671-676.	1.7	5
729	Pharmacogenetics in irritable bowel syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1187-1191.	1.5	5
730	Rifaximin, Microbiota Biology, and Hepatic Encephalopathy. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e195.	1.3	5
731	Pharmacogenetics and the treatment of functional gastrointestinal disorders. <i>Pharmacogenomics</i> , 2017, 18, 1085-1094.	0.6	5
732	Insights on efficacious doses of PAMORA for patients on chronic opioid therapy or opioid-naïve patients. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13250.	1.6	5
733	976 "A Double-Blind, Randomized, Placebo-Controlled, Crossover, Multiple-Dose Study of Tropifexor, a Non Bile Acid Fxr Agonist, in Patients with Primary Bile Acid Diarrhea. <i>Gastroenterology</i> , 2019, 156, S-204-S-205.	0.6	5
734	Utility of the plasma pancreatic polypeptide response to modified sham feeding in diabetic gastroenteropathy and non-ulcer dyspepsia. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13744.	1.6	5
735	Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2840-2842.	2.4	5
736	Audit of Gastrointestinal Manifestations in Patients with Loey's "Dietz Syndrome and Vascular Ehlers-Danlos Syndrome. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1142-1152.	1.1	5
737	Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1974-1980.	1.1	5
738	Associations of Habitual Dietary Intake With Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 234-242.	1.1	5

#	ARTICLE	IF	CITATIONS
739	Differential mRNA Expression in Ileal Mucosal Biopsies of Patients With Diarrhea- or Constipation-Predominant Irritable Bowel Syndrome. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00329.	1.3	5
740	Bile Acid Malabsorption in Patients with Neuroendocrine Tumors. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2517-2525.	1.1	5
741	Beyond Metoclopramide for Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	5
742	Review article: clinical evidence to support current therapies of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13 Suppl 2, 48-53.	1.9	5
743	Bile Acid Diarrhea Is Associated With Increased Intestinal Permeability Compared With Irritable Bowel Syndrome-Diarrhea. <i>Gastroenterology</i> , 2022, 162, 1343-1345.e1.	0.6	5
744	Of actors, bolting horses, and drops in oceans!. <i>Gut</i> , 2003, 52, 619-621.	6.1	4
745	Gastroenterology and Hepatology Clinical Research Update: 2005â€“2006. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1428-1433.	2.4	4
746	Would Free Fatty Acids Enhance Treatment of Obesity?. <i>Gastroenterology</i> , 2007, 133, 1367-1370.	0.6	4
747	Comparison of Small Bowel and Colonic Mucosal Permeability in Ulcerative/Microscopic Colitis, Irritable Bowel Syndrome-Diarrhea, and Healthy Controls by Urinary Saccharide Excretion Measurements. <i>Gastroenterology</i> , 2011, 140, S-707-S-708.	0.6	4
748	Governance of Clinical Research. <i>American Journal of Gastroenterology</i> , 2012, 107, 336-338.	0.2	4
749	Tu1460 Randomized, Placebo-Controlled, Single-Dose, Crossover Study of the Effects of RM-131 in Type 2 Diabetics With Documented Delayed Gastric Emptying. <i>Gastroenterology</i> , 2012, 142, S-839.	0.6	4
750	Sensations of gas and pain and their relationship with compliance during distension in human colon. <i>Neurogastroenterology and Motility</i> , 2012, 24, 646.	1.6	4
751	Pilot trial: Pregabalin on colonic sensorimotor functions in irritable bowel syndrome. <i>Digestive and Liver Disease</i> , 2014, 46, 113-118.	0.4	4
752	Translation of disease associated gene signatures across tissues. <i>International Journal of Data Mining and Bioinformatics</i> , 2015, 11, 301.	0.1	4
753	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 394-399.e2.	2.3	4
754	Tu1793 Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome: A Randomized, Double-Blinded Trial. <i>Gastroenterology</i> , 2016, 150, S948-S949.	0.6	4
755	COL1A1 Mutations Presenting as Descending Perineum Syndrome in a Young Patient With Hypermobility Syndrome. <i>Mayo Clinic Proceedings</i> , 2018, 93, 386-391.	1.4	4
756	Assessing the efficacy of peripherally acting mu-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation. <i>Gut</i> , 2019, 68, 1133-1134.	6.1	4

#	ARTICLE	IF	CITATIONS
757	How does one choose the appropriate pharmacotherapy for pediatric patients with functional dyspepsia?. Expert Opinion on Pharmacotherapy, 2019, 20, 1921-1924.	0.9	4
758	Microbiome: In Search of Mechanistic Information and Relevance. American Journal of Gastroenterology, 2019, 114, 1014-1016.	0.2	4
759	Association between allelic variants in the glucagon-like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance. Neurogastroenterology and Motility, 2020, 32, e13724.	1.6	4
760	Ten Reasons to Think About Bile Acids in Managing Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 511-515.	0.6	4
761	SPECT test to measure gastric accommodation validated with simultaneous barostat measurement. Gastroenterology, 2001, 120, A97-A97.	0.6	4
762	New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 29B-35B.	1.8	4
763	Evaluation of Alosetron Using the New FDA Composite Endpoint Demonstrates Strong Treatment Effect in Females With Severe Irritable Bowel Syndrome With Diarrhea. American Journal of Gastroenterology, 2014, 109, S535.	0.2	4
764	New treatment options for chronic constipation: mechanisms, efficacy and safety. Canadian Journal of Gastroenterology & Hepatology, 2011, 25 Suppl B, 29B-35B.	1.8	4
765	Safety and Efficacy of Eluxadolone in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study. Digestive Diseases and Sciences, 2022, 67, 3911-3921.	1.1	4
766	LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. iDrugs: the Investigational Drugs Journal, 2010, 13, 921-8.	0.7	4
767	Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210786.	1.4	4
768	Clinical trial: a single-centre, randomised, controlled trial of tradipitant on satiation, gastric functions, and serum drug levels in healthy volunteers. Alimentary Pharmacology and Therapeutics, 2022, 56, 224-230.	1.9	4
769	Antroduodenal manometry. Digestive Diseases and Sciences, 1992, 37, 1305-1308.	1.1	3
770	New therapies for functional bowel diseases. Current Gastroenterology Reports, 2000, 2, 355-363.	1.1	3
771	Divergent Views on Managing Clinical Conflicts of Interest—Reply. Mayo Clinic Proceedings, 2007, 82, 1014-1015.	1.4	3
772	Clinical Challenges and Images in GI. Gastroenterology, 2008, 134, 1293-1635.	0.6	3
773	Candidate genes and functional dyspepsia. Neurogastroenterology and Motility, 2009, 21, 94-94.	1.6	3
774	160 Long-Term Follow-Up of Safety and Satisfaction with Bowel Function in Response to Oral Prucalopride in Patients with Chronic Constipation. Gastroenterology, 2009, 136, A-31.	0.6	3

#	ARTICLE	IF	CITATIONS
775	Proximal Megacolon in an Adult. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, e83-e84.	2.4	3
776	2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, e77-e86.	2.4	3
777	High-Fat Diet, Dysbiosis, and Gastrointestinal and Colonic Transit: Is There a Missing Link?. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 257-258.	2.3	3
778	Physiology of the Colon and Its Measurement. , 2019, , 1676-1688.		3
779	Gastroparesis. , 2019, , 23-50.		3
780	Every Breath Test You Take: Practical Advice on Breath Testing Used to Detect Small Intestinal Bacterial Overgrowth. <i>Digestive Diseases and Sciences</i> , 2021, 66, 331-333.	1.1	3
781	Towards a new era with safer μ -opiate receptor analgesia. <i>Gut</i> , 2022, 71, 1-2.	6.1	3
782	Turning Purple with Pain. <i>New England Journal of Medicine</i> , 2021, 385, 549-554.	13.9	3
783	Small bowel motility disorders. <i>Revista De GastroenterologÃa De MÃ©xico</i> , 1994, 59, 120-6.	0.4	3
784	Functional bowel disease: roles of sensation and motility. <i>Swiss Medical Weekly</i> , 2000, 130, 1772-81.	0.8	3
785	Dyspepsia, irritable bowel syndrome, and constipation: review and what's new. <i>Reviews in Gastroenterological Disorders</i> , 2001, 1, 2-17.	0.6	3
786	Treatment of Irritable Bowel Syndrome Using Fecal Microbiota Transplantation: A Step Forward?. <i>Gastroenterology</i> , 2022, 163, 815-817.	0.6	3
787	Increased caloric intake and decreased postprandial fullness with increased BMI are related to greater fasting gastric volume: A controlled study of 170 volunteers. <i>Gastroenterology</i> , 2003, 124, A31.	0.6	2
788	Response to letter from Dr Haans and Professor Masclee. <i>Neurogastroenterology and Motility</i> , 2006, 18, 1042-1042.	1.6	2
789	Pharmacological and non-pharmacological interventions for symptomatic gastroparesis. <i>The Cochrane Library</i> , 2008, , .	1.5	2
790	Dysmotility of the Small Intestine and Colon. , 0, , 1108-1156.		2
791	Genetic Susceptibility to Inflammation is Associated With Colonic Transit and Other Intermediate Phenotypes in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2011, 140, S-152.	0.6	2
792	Guanylate cyclase C signaling: an intestinal secretory pathway where bugs, genes and new drugs intersect. <i>Genome Medicine</i> , 2012, 4, 50.	3.6	2

#	ARTICLE	IF	CITATIONS
793	Disorders of Gastrointestinal Motility. , 2012, , 862-868.		2
794	Disturbances of Gastrointestinal Motility and the Nervous System. , 2014, , 255-271.		2
795	NGM282, Variant of FGF19, is a Gastric and Colonic Prokinetic and Stimulates Bowel Function in Patients with Functional Constipation: Phase 1B, Two-Dose, Placebocontrolled Study. Gastroenterology, 2017, 152, S1315.	0.6	2
796	Large Meckelâ€™s Diverticulum and Dilated Adjacent Small Intestine Presenting With Intestinal Obstruction. Clinical Gastroenterology and Hepatology, 2018, 16, A33.	2.4	2
797	Current and future impact of clinical gastrointestinal research on patient care in diabetes mellitus. World Journal of Diabetes, 2018, 9, 180-189.	1.3	2
798	The Challenges of Gastroparesis: Changing Study Design to Improve Clinical Care. American Journal of Gastroenterology, 2019, 114, 1-3.	0.2	2
799	856 â€“ Assessment of the Impact of Introducing Fecal Bile Acid Diagnostic Test for Bile Acid Diarrhea in 250 Patients in Clinical Practice and on Prediction of Response to Bile Acid Sequestrants. Gastroenterology, 2019, 156, S-188-S-189.	0.6	2
800	A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery. Metabolic Syndrome and Related Disorders, 2020, 18, 406-412.	0.5	2
801	Expanding the phenotypic spectrum of lipomatosis of the sciatic nerve: Earlyâ€™onset colonic diverticular disease. Neurogastroenterology and Motility, 2020, 32, e13917.	1.6	2
802	Epidemiology of gastroparesis: important answers and still more questions. Gut, 2021, 70, 631-632.	6.1	2
803	New Drugs on the Horizon for Functional and Motility Gastrointestinal Disorders. Gastroenterology, 2021, 161, 761-764.	0.6	2
804	Dysmotility of the Small Intestine and Colon. , 0, , 295-310.		2
805	Gastric Motor Functions in Patients With Mood Disorders and Functional Gastroduodenal Symptoms. Psychosomatic Medicine, 2021, 83, 171-176.	1.3	2
806	Treatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility. Gastroenterology and Hepatology, 2013, 9, 51-3.	0.2	2
807	Medical Therapies in the Pipeline for Irritable Bowel Syndrome. Gastroenterology and Hepatology, 2017, 13, 550-552.	0.2	2
808	The Effect of Caloric Intake and Macronutrient Composition on Intestinal Cholesterol Absorption and Bile Acids in Patients with Obesity. American Journal of Physiology - Renal Physiology, 0, , .	1.6	2
809	Colectomy for severe constipation. Digestive Diseases and Sciences, 1988, 33, 1196-1196.	1.1	1
810	Neurogastroenterology: evolving concepts and techniques to study motility and hypersensitivity. Digestive and Liver Disease, 2000, 32, 227-232.	0.4	1

#	ARTICLE	IF	CITATIONS
811	Alosetron. <i>Drugs</i> , 2000, 59, 519-520.	4.9	1
812	Irritable bowel syndrome: newer pharmacological agents acting on the gut. <i>International Congress Series</i> , 2002, 1241, 143-148.	0.2	1
813	A Moveable Feast. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 646-647.	2.4	1
814	Enteric neurodegeneration in ageing. <i>Neurogastroenterology and Motility</i> , 2008, 20, 417-417.	1.6	1
815	W1310 Relationship Between Colonic Motor Functions and Transit in Constipation. <i>Gastroenterology</i> , 2008, 134, A-677.	0.6	1
816	Clarifications about linaclotide. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 15-15.	1.4	1
817	Commentary: fibroblast growth factor 19 in patients with bile acid diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1320-1321.	1.9	1
818	Response to Arnold and Beaves. <i>American Journal of Gastroenterology</i> , 2013, 108, 1539-1540.	0.2	1
819	Tu1798 Characterization of Hypothalamic Hunger and Satiety Signals With Pulsed Arterial Spin Labeling MRI. <i>Gastroenterology</i> , 2014, 146, S-845.	0.6	1
820	Tu2037 Effects of YKP10811, a Selective 5-HT4 Receptor Agonist, in Patients with Functional Constipation: A Randomized, Controlled, Phase II Study. <i>Gastroenterology</i> , 2014, 146, S-902-S-903.	0.6	1
821	676 Validating a Biomarker for Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2014, 146, S-119-S-120.	0.6	1
822	64 RNA Sequencing Shows Transcriptomic Changes in Rectosigmoid Mucosa in Patients With Irritable Bowel Syndrome-Diarrhea. <i>Gastroenterology</i> , 2014, 146, S-18.	0.6	1
823	Mo1289 Comparing Gastroparesis Symptom Severity Between Patients With Idiopathic and Diabetic Gastroparesis: The Gcsi-Dd Reliably Assesses Symptoms From Both Diabetic and Idiopathic Gastroparesis. <i>Gastroenterology</i> , 2014, 146, S-609.	0.6	1
824	Imaging approach to measuring small bowel motility. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G411-G412.	1.6	1
825	Laparoscopy and Laparotomy. , 2016, , 698-701.		1
826	Tumors of the Biliary Tract. , 2016, , 368-373.		1
827	Miscellaneous Diseases of the Stomach. , 2016, , 153-156.		1
828	Zollinger-Ellison Syndrome. , 2016, , 135-139.		1

#	ARTICLE	IF	CITATIONS
829	Tu1809 Small Intestinal Mucosal Expression of Candidate Pathobiological Mechanisms in IBS-Diarrhea (IBS-D) and Healthy Controls. <i>Gastroenterology</i> , 2016, 150, S954.	0.6	1
830	Ulcerative Colitis: Clinical Manifestations and Management. , 2016, , 216-224.		1
831	964 Prevalence of Opioid Analgesic Use Among Patients Presenting to Emergency Department With Abdominal Pain That Is Investigated With Emergent Abdominal CT Scan. <i>Gastroenterology</i> , 2016, 150, S192-S193.	0.6	1
832	Relationship between Gastric Emptying or Gastric Accommodation and Postprandial Symptoms Observed After Ingestion of a Maximum Volume of a Nutrient Drink in 285 Participants. <i>Gastroenterology</i> , 2017, 152, S932-S933.	0.6	1
833	Effects of Liraglutide on Gastric Emptying, Gastric Accommodation, Satiety and Satiety after 16 Weeks' Treatment: A Single-Center, Randomized, Placebo-Controlled Trial in 32 Patients. <i>Gastroenterology</i> , 2017, 152, S633-S634.	0.6	1
834	Anal Achalasia: The Rat Tail Gas Sign. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, e124.	2.4	1
835	Sa1947 " Randomized, Double-Blind, Placebo-Controlled Trial of Colesevelam in Patients with Bile Acid Diarrhea: Effects on Fecal Bile Acids, Colonic Transit, and Bowel Functions. <i>Gastroenterology</i> , 2019, 156, S-464-S-465.	0.6	1
836	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. <i>Bone Marrow Transplantation</i> , 2019, 54, 1898-1907.	1.3	1
837	Editorial: effects of vildagliptin on GLP-1 levels, gastric motor function and food intake. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1362-1363.	1.9	1
838	Sa1715 ELOBIXIBAT, ILEAL BILE ACID TRANSPORTER INHIBITOR, INCREASES FECAL BILE ACIDS IN PATIENTS WITH CHRONIC CONSTIPATION. <i>Gastroenterology</i> , 2020, 158, S-394-S-395.	0.6	1
839	Mo1785 INCREASED FECAL BILE ACID EXCRETION IN A MAJORITY OF PATIENTS WITH DIARRHEA ASSOCIATED WITH MICROSCOPIC COLITIS, ULCERATIVE COLITIS, CROHN'S DISEASE, AND QUIESCENT CELIAC DISEASE. <i>Gastroenterology</i> , 2020, 158, S-919-S-920.	0.6	1
840	Gastrointestinal motility evaluation in children with orthostatic intolerance: Mayo Clinic experience. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13863.	1.6	1
841	Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 185-186.	1.9	1
842	Polyethylene glycol-based laxatives for chronic constipation " Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 110-111.	3.7	1
843	Clinical presentation and characteristics of pelvic floor myofascial pain in patients presenting with constipation. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13845.	1.6	1
844	BAD on the Runs: Improved Diagnosis of Idiopathic Bile Acid Diarrhea. <i>Digestive Diseases and Sciences</i> , 2022, 67, 745-747.	1.1	1
845	Su084 DIAGNOSING BILE ACID DIARRHEA IN PEDIATRIC IBS-D USING 48 HOURS FECAL BILE ACID TESTING. <i>Gastroenterology</i> , 2021, 160, S-609-S-610.	0.6	1
846	Cystic Diseases of the Liver and Biliary Tract. , 0, , 361-367.		1

#	ARTICLE	IF	CITATIONS
847	Acute Viral Hepatitis. , 0, , 374-386.		1
848	Gastrointestinal Dilation and Stent Placement. , 0, , 643-663.		1
849	Liver: Anatomy, Microscopic Structure, and Cell Types. , 0, , 50-57.		1
850	Adynamic ileus in severe Guillain-Barré syndrome. Muscle and Nerve, 2001, 24, 963-965.	1.0	1
851	A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects Receiving Codeine or Placebo: 2017 Fellows-in-Training Award (Functional Bowel Disease Category) 2017 Presidential Poster Award. American Journal of Gastroenterology. 2017, 112, S230.	0.2	1
852	Management of Gastroparesis.. Gastroenterology and Hepatology, 2021, 17, 515-525.	0.2	1
853	Choosing G-POEM or other treatments for gastroparesis. Gut, 2022, 71, 2145-2146.	6.1	1
854	What is the Relevance of a Systematic Review of Pharmacological Management in Irritable Bowel Syndrome to Older People?. Journal of the American Geriatrics Society, 2001, 49, 1249-1252.	1.3	0
855	GIH clinical research 2003-2004: The year in review. Clinical Gastroenterology and Hepatology, 2004, 2, 1043-1047.	2.4	0
856	GIH Clinical Research Update: 2004-2005. Clinical Gastroenterology and Hepatology, 2005, 3, 1161-1166.	2.4	0
857	OC-069...Efficacy of 12-week treatment with prucalopride (resolor) in patients with chronic constipation: combined results of three randomised, double-blind, placebo-controlled phase 3 trials. Gut, 2010, 59, A28.3-A29.	6.1	0
858	Response to Odunda et al. Results for CM3 Cannot Be Extrapolated to Alginates in General Obesity, 2010, 18, 2070-2070.	1.5	0
859	Response to Sandner-Kiesling. American Journal of Gastroenterology, 2011, 106, 2200-2201.	0.2	0
860	Letter: effects of oxycodone and tapentadol dosage on gastrointestinal function - author's reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 689-689.	1.9	0
861	Chrelin and motilin receptor agonists: a long and winding misconception. Neurogastroenterology and Motility, 2013, 25, 1003-1003.	1.6	0
862	Reply. Gastroenterology, 2013, 145, 694.	0.6	0
863	Editorial: colesevelam effects on faecal bile acids in IBS with diarrhoea - author's reply. Alimentary Pharmacology and Therapeutics, 2015, 41, 697-697.	1.9	0
864	Reply. Clinical Gastroenterology and Hepatology, 2015, 13, 2383.	2.4	0

#	ARTICLE	IF	CITATIONS
865	Colon: anatomy and structural anomalies. , 2016, , 24-29.		0
866	Capsule and Small Bowel Endoscopy. , 2016, , 621-625.		0
867	Tumors of the Stomach. , 2016, , 149-152.		0
868	Oral Manifestation of Gastrointestinal Diseases. , 2016, , 574-581.		0
869	Short bowel syndrome. , 2016, , 189-201.		0
870	Cystic Lesions of the Pancreas. , 2016, , 324-328.		0
871	Chronic Hepatitis B Viral Infection. , 2016, , 387-391.		0
872	Response to â€œTeduglutide and Intestinal Permeability in Short Bowel Syndromeâ€: Journal of Parenteral and Enteral Nutrition, 2016, 40, 1087-1088.	1.3	0
873	Gastritis and Gastropathy. , 2016, , 140-148.		0
874	Hepatitis C Virus Infection. , 2016, , 392-396.		0
875	Management of Upper Gastrointestinal Hemorrhage Related to Portal Hypertension. , 2016, , 664-674.		0
876	Gastrointestinal Manifestations of Immunological Disorders. , 2016, , 509-514.		0
877	PTU-137â€¦Enhanced Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by History and Diagnostic Evaluation: Abstract PTU-137 Table 1. Gut, 2016, 65, A125.1-A125.	6.1	0
878	Abdominal electroacupuncture demonstrates an increase in complete spontaneous bowel movements. Evidence-Based Medicine, 2017, 22, 101-101.	0.6	0
879	A Selection of the Best AGA Abstracts of DDW 2017. Gastroenterology, 2017, 153, e1-e5.	0.6	0
880	Anniversary Tribute From the Editors of Clinical Gastroenterology and Hepatology. Clinical Gastroenterology and Hepatology, 2017, 15, 1823-1827.	2.4	0
881	The Management of Obesity. , 2017, , 47-57.		0
882	Editorial: patient assessment of constipationâ€symptoms (PACâ€SYM) questionnaire has a minimal important difference. Alimentary Pharmacology and Therapeutics, 2018, 47, 138-139.	1.9	0

#	ARTICLE	IF	CITATIONS
883	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 1364.	2.4	0
884	Letter to the Editor: "Defects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetes" Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5106-5107.	1.8	0
885	Full-thickness evaluation from endoscopic rectal sampling: an important first step in tissue diagnosis of colonic dysmotility. Gastrointestinal Endoscopy, 2019, 89, 1248-1250.	0.5	0
886	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 214.	2.4	0
887	Personalized management in functional gastrointestinal disorders based on genomics: hope at last or just feigned praise?. Therapeutic Advances in Gastroenterology, 2019, 12, 1756283X1882279.	1.4	0
888	PWE-076...Efficacy of Pharmacological Therapies in Patients with Irritable Bowel Syndrome with Diarrhoea: Network Meta-analysis. , 2019, , .		0
889	Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis? Author's reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 546-547.	1.9	0
890	Reply. Gastroenterology, 2020, 158, 1842-1843.	0.6	0
891	Disturbances of Gastrointestinal Motility and the Nervous System. , 2021, , 217-234.		0
892	Pharmacological Treatments for Constipation and Opioid-Induced Constipation. , 2021, , .		0
893	Gastric dysmotility at the organ level in gastroparesis. , 2021, , 47-67.		0
894	A vision of the future for gastroparesis. , 2021, , 527-538.		0
895	Reduced gastric accommodation in patients with Parkinson's disease: A case series. Neurogastroenterology and Motility, 2021, 33, e14143.	1.6	0
896	Editorial: finding the ideal prokinetic for gastroparesis "we are not there yet. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 212-213.	1.9	0
897	A Review of Irritable Bowel Syndrome "Reply. JAMA - Journal of the American Medical Association, 2021, 326, 189.	3.8	0
898	Editorial: understanding IBS pathophysiology through "converging channels" of research "authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 1215-1216.	1.9	0
899	MOTILITY DISORDERS. , 2009, , 475-486.		0
900	Physiology of the Colon and Its Measurement. , 2013, , 1728-1739.		0

#	ARTICLE	IF	CITATIONS
901	Tumors of the Small Intestine. , 0 , 202-207.		0
902	Computed Tomography of the Gastrointestinal Tract. , 0 , 756-767.		0
903	Complications of AIDS and Other Immunodeficiency States. , 0 , 501-508.		0
904	Helminthic Infections of the Gastrointestinal Tract and Liver. , 0 , 524-543.		0
905	Endoscopic Retrograde Cholangiopancreatography: Diagnostic and Therapeutic. , 0 , 634-642.		0
906	Approach to the Patient with Ascites and Its Complications. , 0 , 447-458.		0
907	Obesity: Treatment and Complications. , 0 , 491-494.		0
908	Esophageal Neoplasms. , 0 , 93-101.		0
909	Gastrointestinal Manifestations of Systemic Diseases. , 0 , 544-553.		0
910	Radiation Injury in the Gastrointestinal Tract. , 0 , 597-602.		0
911	Endoscopic Mucosal Biopsy: Histopathological Interpretation. , 0 , 878-930.		0
912	Miscellaneous diseases of the small intestine. , 0 , 208-215.		0
913	Diseases of the Peritoneum, Retroperitoneum, Mesentery, and Omentum. , 0 , 484-490.		0
914	Positron Emission Tomography in the Gastrointestinal Tract. , 0 , 782-803.		0
915	Endoscopic Diagnosis and Treatment of Nonvariceal Upper Gastrointestinal hemorrhage. , 0 , 675-679.		0
916	Primary Sclerosing Cholangitis and Other Cholangiopathies. , 0 , 354-360.		0
917	Abdominal Angiography. , 0 , 820-841.		0
918	Role of Nutrition in Understanding Common Gastrointestinal Disorders. , 2017 , 129-138.		0

#	ARTICLE	IF	CITATIONS
919	Future directions in functional gastrointestinal disorders – microbiota, faecal transplants and pharmaceutical approaches. , 2017, , 269-278.		0
920	Autonomic Nervous System Dysfunction and the Gastrointestinal Tract. , 2020, , 197-212.		0
921	Colonic Transit. , 2020, , 638-648.		0
922	Clinical subgroups of chronic constipation: exploring the potential of polyethylene glycol. Italian Journal of Gastroenterology and Hepatology, 1999, 31 Suppl 3, S253-4.	0.5	0
923	New therapeutic approaches in irritable bowel syndrome. European Review for Medical and Pharmacological Sciences, 2008, 12 Suppl 1, 139-40.	0.5	0
924	Single-center Clinical Experience of Diarrhea in Patients Treated With Sorafenib Shows Rare Development of Pancreatic Atrophy. , 2022, 1, 296-298.		0
925	Letter: elobixibatting for the long run – authors – reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 769-770.	1.9	0
926	Rectal Evacuation Disorders in Patients Presenting With Chronic Functional Diarrhea. , 2022, 1, 549-552.		0
927	Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone – authors – reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 542-543.	1.9	0